03/02/2021

Date Journal Title Study type Country Authors Link Trial identifier Intervention Main question

ESCAPE: An Open‐Label Trial of https://www.medrxiv.or To investigate the outcome of RCT phase anakinra 26‐Jan‐21 BMJ Personalized Immunotherapy in Critically Greece Karakike E, et al. g/content/10.1101/2021 NCT04339712 personalized immunotherapy II tocilizumab Ill COVID‐19 Patients .01.20.21250182v1 in critical COVID‐19.

The effect of early treatment with To evaluate the efficacy of a https://www.thelancet.c ivermectin on viral load, symptoms and single dose of ivermectin om/journals/eclinm/arti EClinical humoral response in patients with non‐ reduce the transmission of 26‐Jan‐21 RCT Spain Chaccour C. et al cle/PIIS2589‐ NCT04390022 Ivermectin Medicine severe COVID‐19: A pilot, double‐blind, SARS‐CoV‐2 when 5370(20)30464‐ placebo‐controlled, randomized clinical administered early after 8/fulltext#%20 trial disease onset.

To determine whether https://www.thelancet.c Effect of anakinra versus usual care in adults anakinra could improve The Lancet om/journals/lanres/artic in hospital with COVID‐19 and mild‐to‐ Internation The CORIMUNO‐19 anakinra outcomes in patients in 22‐Jan‐21 Respiratory RCT le/PIIS2213‐ NCT04341584 moderate pneumonia (CORIMUNO‐ANA‐1): a al Collaborative group tocilizumab hospital with mild‐to‐ medicine 2600(20)30556‐ randomised controlled trial moderate COVID‐19 7/fulltext pneumonia.

To determine the effect of Effect of Bamlanivimab as Monotherapy bamlanivimab monotherapy https://jamanetwork.co bamlanivimab/bamla or in Combination With Etesevimab on and combination therapy with 21‐Jan‐21 JAMA RCT USA Gottlieb R.L., et m/journals/jama/fullarti NCT04427501 nivimab and Viral Load in Patients With Mild to bamlanivimab and etesevimab cle/2775647 etesevimab Moderate COVID‐19 (BLAZE‐1 study) on SARSCoV‐2 viral load in mild to moderate COVID‐19. Safety and immunogenicity of an BBV152: whole‐virion inactivated SARS‐CoV‐2 inactivated SARS‐CoV‐2 Lancet Safety and immunogenicity of an Vaccine vaccine, BBV152: a vaccine formulated with a toll‐ 21‐Jan‐21 Infectionus inactivated SARS‐CoV‐2 vaccine, BBV152: India Ella R., et al. NCT04471519 BVB152 vaccine Phase I double‐blind, like receptor 7/8 agonist diseases a double‐blind, randomised, phase 1 trial randomised, phase 1 molecule adsorbed to alum trial ‐ The Lancet (AlgelIMDG) or alum (Algel) Infectious Diseases

Effect of tocilizumab on clinical outcomes Does tocilizumab improves at 15 days in patients with severe or https://www.bmj.com/c 20‐Jan‐21 BMJ RCT Brazil Veiga, V.C. et al. NCT04403685 tocilizumab clinical outcomes for patients critical coronavirus disease 2019: ontent/372/bmj.n84 with severe or COVID‐19?. randomised controlled tria

Interim Results of a NCT04436276. The safety and Interim Results of a Phase 1–2a Trial of vaccine Phase 1–2a Trial of 13‐Jan‐21 NEJM USA Sadoff J., et al. opens in new Ad26.COV2.S vaccine immunogenicity profiles of Ad26.COV2.S Covid‐19 Vaccine Phase I/IIa Ad26.COV2.S Covid‐19 tab. Ad26.COV2 Vaccine | NEJM

To assess whether convalescent plasma with high antibody levels https://www.medrxiv.or rather than low antibody expanded Early Safety Indicators of COVID‐19 g/content/10.1101/2020 levels is associated with a 13‐Jan‐21 NEJM access USA Joyner et al. NCT04338360 Convalescent plasma Convalescent Plasma in 5,000 Patients .05.12.20099879v1.full.p lower risk of program df death. Primary outcome: death within 30 days after plasma transfusion.

Short term, high‐dose vitamin D https://pmj.bmj.com/co Do high doses of Postgraduate supplementation for COVID‐19 disease: a ntent/early/2020/11/12 cholecalciferol lead to SARS‐ 11‐Nov‐20 RCT India Rastogi et al. NCT04459247 Vitamin D Medical Journal randomised, placebo‐controlled, study /postgradmedj‐2020‐ CoV‐2 negativity in greater (SHADE study) 139065 proportions?

Safety and immunogenicity of S‐Trimer (SCB‐ https://www.thelancet.c 2019), a protein subunit vaccine candidate for Phase I om/journals/lancet/artic Dose‐finding and adjuvant Multinatio 29‐Jan‐21 The Lancet COVID‐19 in healthy adults: a phase 1, vaccine Richmond et al. le/PIIS0140‐ NCT04405908 S‐Trimer (SCB‐2019) justification of SCB‐2019 nal randomised, double‐blind, placebo‐controlled trial 6736(21)00241‐ vaccine trial 5/fulltext https://www.thelancet.c Safety and efficacy of an rAd26 and rAd5 Phase III om/journals/lancet/artic vector‐based heterologous prime‐boost Gam‐COVID‐Vac Efficacy and safety of Gam‐ 02‐Feb‐21 The Lancet vaccine Russia Logunov et al. le/PIIS0140‐ NCT04530396 COVID‐19 vaccine: an interim analysis of a (Sputnik V) COVID‐Vac randomised controlled phase 3 trial in Russia trial 6736(21)00234‐ 8/fulltext

Early High‐Titer Plasma Early High‐Titer Plasma Does convalescent plasma Therapy to Prevent 06‐Jan‐21 NEJM Therapy to Prevent Severe RCT Argentina Libster R, et al. NCT04479163 Convalescent plasma reduce the development of Severe Covid‐19 in Older Covid‐19 in Older Adults severe respiratory disease? Adults | NEJM

Efficacy, Safety, and https://www.nejm.org/d Immunogenicity of mRNA‐ Efficacy and Safety of the mRNA‐1273 Vaccine ‐ oi/full/10.1056/NEJMoa mRNA‐1273 SARS‐CoV‐ 30‐Dec‐21 NEJM USA Baden LR, et al. NCT04470427 1273 Vaccine in Adults Aged SARS‐CoV‐2 Vaccine phase III 2035389?query=feature 2 Vaccine 18 Years and Older to Prevent d_coronavirus COVID‐19

https://www.medrxiv.or Enisamium is an inhibitor of the SARS‐CoV‐2 Efficacy and safety of RNA polymerase and shows improvement of Multinatio g/content/10.1101/2021 12‐Jan‐21 MedRxiv RCT Holubovska et al. NCT04682873 enisamium enisamium at COVID‐19 recovery in COVID‐19 patients in an interim nal .01.05.21249237v1.full‐ patients analysis of a clinical trial text

Safety and immunogenicity of SARS‐CoV‐2 Vaccine https://www.medrxiv.or recombinant protein vaccine formulations in Multinatio CoV2 preS dTM Safety and imunogenicity of 20‐Jan‐21 MedRxiv trial phase Goepfert et al. g/content/10.1101/2021 NCT04537208 healthy adults: a randomised, placebo‐ nal vaccine CoV2 preS dTM vaccine controlled, dose‐ranging study I/II .01.19.20248611v1

https://link.springer.co Annals of Pilot trial of high‐dose vitamin C in critically ill Effect of high doses of vitamin 09‐Jan‐21 RCT China Zhang et al. m/article/10.1186/s136 NCT04264533 Vitamin C Intensive Care COVID‐19 patients C 13‐020‐00792‐3

Efficacy and safety of favipiravir, an oral International https://www.sciencedir RNA‐dependent RNA polymerase Efficacy and safety of Journal of ect.com/science/article/ CTRI/2020/05/0 01‐Feb‐21 inhibitor, in mild‐to‐moderate COVID‐19: RCT India Udwadia et al. favipiravir favipiravir in adults with mild‐ Infectious pii/S120197122032453X 25114 A randomized, comparative, open‐label, to‐moderate COVID‐19 Diseases ?via%3Dihub multicenter, phase 3 clinical trial ISRCTN8995142 Safety and efficacy of the ChAdOx1 nCoV‐ https://www.thelancet.c phase 4, 19 vaccine (AZD1222) against SARS‐CoV‐ om/journals/lancet/artic To test the safety and efficacy I/II/III Multinatio NCT04324606, ChAdOx1 nCoV‐19 08‐Dec‐20 Lancet 2: an interim analysis of four randomised Voysey et al. le/PIIS0140‐ of the ChAdOx1 nCoV‐19 vaccine nal NCT04400838, vaccine controlled trials in Brazil, South Africa, 6736(20)32661‐ vaccine trial and and the UK 1/fulltext NCT04444674

Effect of Baricitinib plus baricitinib (≤14 days) plus Baricitinib plus Remdesivir for Remdesivir for Baricitinib plus remdesivir (≤10 days) vs. 11‐Dec‐20 NEJM RCT USA Kalil A.C., et al NCT04401579 Hospitalized Adults with Covid‐19 Hospitalized Adults with Remdesivir remdesivir alone Covid‐19 | NEJM in hospitalized adults with Covid‐19 To test the safety and efficacy https://www.nejm.org/d Tocilizumab in Patients Hospitalized with of tocilizumab in hospitalized 17‐Dec‐20 NEJM RCT USA Salama et al. oi/10.1056/NEJMoa2030 NCT04372186 tocilizumab Covid‐19 Pneumonia patients with Covid‐19 340 pneumonia

https://assets.researchs Exogenous Surfactant Versus Placebo in quare.com/files/rs‐ the Treatment of Moderate and Severe IRCT200912010 Is surfactant effective in 31‐Dec‐20 Preprint RCT Iran Ghahremani et al. 136365/v1/adcad24b‐ surfactant ARDS in COVID19: The Pilot Study of a 02804N12 COVID‐19 paients? f7ed‐477b‐a235‐ Clinical Trial 235f84f8ce1b.pdf WHO mortality trial of four remdesivir, Repurposed Antiviral repurposed antiviral drugs — hydroxychloroquine Repurposed Antiviral Drugs for Covid‐19 Multinatio WHO Soidarity Trial Drugs for Covid‐19 — remdesivir, 02‐Dec‐20 NEJM RCT NCT04315948 (HCQ), lopinavir, and — Interim WHO Solidarity Trial Results nal Consortium Interim WHO Solidarity hydroxychloroquine (HCQ), interferon beta‐1a Trial Results | NEJM lopinavir, and interferon beta‐ (IFN) 1a (IFN)— in patients mRNA 1273 vaccine Durability of Responses Phase I immunogenicity 3 months Durability of Responses after SARS‐CoV‐2 mRNA‐ 03‐Dec‐20 NEJM vaccine USA Widge A.T., et al. NCT04283461 mRNA 1273 vaccine after second after SARS‐CoV‐2 mRNA1273 Vaccination 1273 Vaccination | trial vaccination NEJM

Safety and immunogenicity of INO‐4800 Phase I https://www.sciencedir EClinicalMedici DNA vaccine against SARS‐CoV‐2: A INO‐4800 DNA Safety and immunogenicity of 24‐Dec‐20 vaccine USA/UK Tebas et al. ect.com/science/article/ NCT04336410 ne preliminary report of an open‐label, vaccine INO‐4800 vaccine trial pii/S2589537020304338 Phase 1 clinical trial

Phase 1/2 trial of SARSCoV‐2 vaccine Safety and exploratory Phase I/II https://www.nature.co ChAdOx1 nCoV‐19 with a booster dose ChAdOx1 nCoV‐19 humoral and cellular 17‐Dec‐20 Nature Med. vaccine UK Barrett J.R., et al. m/articles/s41591‐020‐ NCT04400838 induces multifunctional antibody vaccine AZD1222 immunogenicity of the trial 01179‐4 responses AZD1222 vaccine Interim study results: effects REGN‐COV2, a of high viral loads with REGN‐COV2, a Neutralizing Neutralizing Antibody REGN‐COV2 antibody complications 17‐Dec‐20 NEJM Antibody Cocktail, in RCT USA Weinreich D.M NCT04425629 Cocktail, in Outpatients cocktail and death from coronavirus Outpatients with Covid‐19 with Covid‐19 | NEJM disease 2019 (Covid‐19)‐REGN‐ COV2 Safety and immunogenicity clinical trial of an inactivated SARS‐CoV‐2 vaccine, Phase I/II https://www.medrxiv.or To test the immunogenicity BBV152 (a phase 2, double‐blind, inactivated SARS‐CoV‐ 22‐Dec‐20 preprint ‐ BMJ vaccine India Raches et al. g/content/10.1101/2020 NCT04471519 and safety of BBV152: 3 µg randomised controlled trial) and the 2 vaccine, BBV152 trial .12.21.20248643v1 and 6 µg with Algel‐IMDG. persistence of immune responses from a phase 1 follow‐up report A Neutralizing ACTIV‐3/TICO LY‐ To test the effect of this A Neutralizing Monoclonal Antibody for Monoclonal Antibody 22‐Dec‐20 NEJM RCT Denmark CoV555 Study NCT04501978 LY‐CoV555 antibody in patients who are Hospitalized Patients with Covid‐19 for Hospitalized Patients Group hospitalized with Covid‐19. with Covid‐19 | NEJM To test the effect of Tocilizumab on multi‐organ Efficacy of Tocilizumab in Efficacy of Tocilizumab dysfunction in a phase 3 10‐Dec‐20 NEJM Patients Hospitalized with RCT USA Stone J.H., et al in Patients Hospitalized NCT04356937 tocilizumab randomized controlled trial Covid‐19 with Covid‐19 | NEJM among hospitalized patients with COVID‐19 infection. https://bmcinfectdis.bio To determine the effect of Effect of Arbidol (Umifenovir) on COVID‐ medcentral.com/articles IRCT201807250 14‐Dec‐20 BMC Infect Dis RCT Iran Marzieh et al. Arbidol (Umifenovir) Arbidol (ARB) on COVID‐19 19: a randomized controlled trial. /10.1186/s12879‐020‐ 40596N2 disease. 05698‐w

https://trialsjournal.bio To test the efficacy of Interferon ß‐1a (IFNß‐1a) in COVID‐19 EudraCT 2020‐ medcentral.com/articles Interferon ß‐1a (IFNß‐ Interferon‐β‐1a (IFNβ‐1a), in 23‐Dec‐20 Trials patients (INTERCOP): study protocol for a RCT Italy Bosi et al. 002458‐25, /10.1186/s13063‐020‐ 1a) COVID‐19 patients in an open randomized controlled trial. NCT04449380 04864‐4 label, randomized clinical trial. To evaluate the efficacy and Safety and Efficacy of safety of BNT162b2 is a lipid phase II NCT04368728. Safety and Efficacy of the BNT162b2 the BNT162b2 mRNA nanoparticle–formulated, 10‐Dec‐20 NEJM vaccine USA Polack F.P., et al. opens in new BNT162b2 vaccine mRNA Covid‐19 Vaccine Covid‐19 Vaccine | nucleoside‐modified RNA trial tab NEJM vaccine that encodes a prefusion stabilized, https://academic.oup.co Journal of Sofosbuvir and daclatasvir for the m/jac/advance‐ IRCT202004030 Is sofosbuvir/daclatasvir 18‐Dec‐20 Antimicrobial treatment of COVID‐19 outpatients: a RCT Iran Roozbeh et al. article/doi/10.1093/jac/ sofosbuvir, daclatasvir 46926N1 effective in COVID‐19 patiets? Chemotherapy double‐blind, randomized controlled trial dkaa501/6041772?login =true https://journals.lww.co m/ccejournal/Fulltext/2 To asses the efficacy and Intravenous Immunoglobulin Plus 16 November Critical Care George Sakoulas, et 020/11000/Intravenous safety of IV immunoglobulin in Methylprednisolone Mitigate Respiratory RCT USA NCT04411667 Immunoglobulins 2020 Explorations al. _Immunoglobulin_Plus_ hospitalized COVID‐19 Morbidity in Coronavirus Disease 2019 Methylprednisolone.14. patients. aspx To evaluate the effect of Biological Trace Do Zinc Supplements Enhance the Clinical https://link.springer.co combining 23 November Sherief Abd‐ Zinc, Element Efficacy of Hydroxychloroquine?: a RCT Egypt m/article/10.1007/s120 NCT04447534 chloroquine/hydroxychloroqui 2020 Elsalam, et al. Hydroxychloroquine Research Randomized, Multicenter Trial 11‐020‐02512‐1 ne and zinc in the treatment of COVID‐19 patients. Effect of Vitamin D3 Supplementation vs To determine if vitamin D3 https://www.medrxiv.or Placebo on Hospital Length of Stay in supplementation can reduce g/content/10.1101/2020 17‐Nov MedRxiv Patients with Severe COVID‐19: A RCT Brazil Murai et al. NCT04449718 Vitamin D3 hospital length of stay in .11.16.20232397v1.full.p Multicenter, Double‐blind, Randomized 3 hospitalized patients with df Controlled Trial severe COVID‐19? To determine whether a https://www.medrxiv.or single, 180 mcg subcutaneous Peginterferon Lambda‐1a for treatment g/content/10.1101/2020 Peginterferon Lambda‐ dose of Peginterferon Lambda‐ 23‐Nov MedRxiv of outpatients with uncomplicated COVID‐ RCT USA Jagannathan et al. NCT04331899 .11.18.20234161v1.full.p 1a 1a (Lambda) could shorten the 19: a randomized placebo‐controlled trial df duration of viral shedding or symptoms in patients with To evaluate the efficacy of https://www.medrxiv.or convalescent plasma with high Prevention of severe COVID‐19 in the g/content/10.1101/2020 titers of SARS‐CoV2 antibody 21‐Nov MedRxiv RCT Argentina Libster et al. NCT04479163 Convalescent plasma elderly by early hightiter plasma .11.20.20234013v1.full.p administered within 72 hours df of mild symptoms to elderly patients with Covid‐19 To estimate the efficacy and A two‐arm, randomized, controlled, multi‐ https://www.medrxiv.or safety of Itolizumab in the centric, open‐label Phase‐2 study to g/content/10.1101/2020 CTRI/2020/05/0 treatment of cytokine release 02‐Dec MedRxiv evaluate the efficacy and safety of RCT India Kumar et al. Itolizumab .12.01.20239574v1.full.p 24959 syndrome in patients with Itolizumab in moderate to severe ARDS df moderate to severe acute patients due to COVID‐19 respiratory distress syndrome 5‐Alpha‐Reductase Inhibitors Reduce To determine if 5‐alpha‐ https://www.medrxiv.or Remission Time of COVID‐19: Results reductase inhibitors (5ARis) g/content/10.1101/2020 18‐Nov MedRxiv From a Randomized Double Blind Placebo RCT Brazil, USA Cadegiani et al. NCT04446429 Dutasteride are a beneficial treatment for .11.16.20232512v1.full.p Controlled Interventional Trial in 130 COVID‐19 if given after SARS‐ df SARSCoV‐2 Positive Men CoV‐2 infection https://reader.elsevier.c To test the effect Pentoxifylline decreases serum LDH levels om/reader/sd/pii/S1567 Pentoxifylline (PTX) on International and increases lymphocyte count in COVID‐ 576920336766?token=E parameters such as LDH, 11‐Nov Immunopharma RCT Mexico Maldonado et al. COF‐002495 Pentoxifylline 19 patients: Results from an external pilot DD4B561C8D7F700793B lymphocyte count, days of cology study 55AFFA9EE8F0CD28010 hospitalization, mortality, and BE3E0CADC0EF90237E4 the need for intubation on hydroxychloroquine, https://www.nejm.org/d Repurposed Antiviral Drugs for Covid‐19 Multinatio WHO Solidarity Trial ISRCTN8397115 lopinavir/ritonavir, effects of drugs on in‐hospital 02‐Dec‐20 NEJM RCT oi/10.1056/NEJMoa2023 — Interim WHO Solidarity Trial Results nal Consortium 1, NCT04315948 interferon beta1, mortality 184 remdesivir

Does postexposure A Cluster‐Randomized Trial of https://www.nejm.org/d prophylaxis with 24‐Nov‐20 NEJM Hydroxychloroquine for Prevention of RCT Spain Mitjà et al. oi/10.1056/NEJMoa2021 NCT04304053 Hydroxychloroquine hydroxychloroquine prevent Covid‐19 801 SARS‐CoV‐2 infection?

Is treatment with https://www.nejm.org/d convalescent plasma A Randomized Trial of Convalescent 24‐Nov‐20 NEJM RCT Argentina Simonovich et al. oi/10.1056/NEJMoa2031 NCT04383535 Convalescent plasma associated with improved Plasma in Covid‐19 Severe Pneumonia 304 clinical outcomes in COVID‐19 patients? Safety and immunogenicity of ChAdOx1 https://www.sciencedir nCoV‐19 vaccine administered in a prime‐ phase II/III NCT04400838, Safety and immunogenicity of ect.com/science/article/ 19‐Nov‐20 The Lancet boost regimen in young and old adults vaccine UK Ramasamy et al. ISRCTN ChAdOx1 vaccine ChAdOx1 vaccine in young and pii/S0140673620324661 (COV002): a single‐blind, randomised, trial 15281137 old adults ?via%3Dihub controlled, phase 2/3 trial Safety, tolerability, and immunogenicity https://www.sciencedir of an inactivated SARS‐CoV‐2 vaccine in Safety, tolerability and Lancet Infect. I/II vaccine ect.com/science/article/ 18‐Nov‐20 healthy adults aged 18–59 years: a China Zhang et al. NCT04352608 CoronaVac vaccine immunogenicity of CoronaVac Dis. trial pii/S1473309920308434 randomised, double‐blind, placebo‐ vaccine ?via%3Dihub controlled, phase 1/2 clinical trial.

Randomized controlled trial of https://www.medrxiv.or Pilot study designed to inform convalescent plasma therapy against Bahrain, g/content/10.1101/2020 04‐Nov MedRxiv RCT Al Qahtani et al. NCT04356534 Convalescent plasma the design of a definitive standard therapy in 2 patients with Ireland .11.02.20224303v1.full.p phase 3 clinical trial. severe COVID‐19 disease df

https://www.medrxiv.or To evaluate a single Peginterferon‐lambda for the treatment g/content/10.1101/2020 subcutaneous injection of 12/11/2020 MedRxiv RCT Canada Feld et al. NCT04354259 Peginterferon of COVID‐19 in outpatients .11.09.20228098v1.full.p peginterferon‐lambda in df outpatients with COVID‐19. https://reader.elsevier.c Evaluating the effects of Intravenous om/reader/sd/pii/S1567 To investigate the potential International Immunoglobulin (IVIg) on the 576920336729?token=1 IRCT201512270 Intravenous usefulness of IVIg for the 13‐Nov Immunopharma RCT Iran Tabarsi et al. management of severe COVID‐19 cases: A 3C23CAB7F2F51222936F 25726N20 Immunoglobulin management of severe cases cology randomized controlled trial 6967643ECEC50F680C6C of Covid‐19. 1B600298B1211225F0D To evaluate the therapeutic Randomized Controlled Open Label Trial International https://www.sciencedir effectiveness of favipiravir on the Use of Favipiravir Combined with 9 November 2020 Journal of ect.com/science/article/ Favipiravir, interferon combined with inhaled Inhaled Interferon beta‐1b in Hospitalized RCT Oman Faryal Khamis, et al. NA (preprint) Infectious pii/S1201971220323195 beta‐1b interferon beta‐1b in adult Patients with Moderate to Severe COVID‐ Diseases ?via%3Dihub patients hospitalized with 19 Pneumonia moderate to severe COVID‐19 https://academic.oup.co Clinical Randomized, double‐blinded and placebo‐ Phase 2 Assess the safety and m/cid/advance‐ Preprint Infectious controlled phase II trial of an inactivated vaccine China Yanchun Che, et al. NCT04412538 Inactivated vaccine immunogenitcity of this article/doi/10.1093/cid/ Diseases SARS‐CoV‐2 vaccine in healthy adults trial inactiviated vaccine ciaa1703/5962856 To evaluate the efficacy of PEP International Post‐exposure prophylaxis with https://www.sciencedir with HCQ for the prevention 6 November 2020 Journal of hydroxychloroquine for the prevention of Deba Prasad ect.com/science/article/ of COVID‐19 in asymptomatic RCT India NCT04408456 Hydroxychloroquine (in press) Antimicrobial COVID‐19, a myth or a reality? The PEP‐ Dhibar, et al. pii/S0924857920304350 non‐HCW in‐ dividuals who Agents CQ Study ?via%3Dihub were at risk for SARS‐CoV‐2 infection To assess the safety, tolerability, and Phase 1 trial of a Candidate Recombinant Phase 1 https://www.medrxiv.or immunogenicity of CoVLP at Preprint MedRxiv Virus‐Like Particle Vaccine for Covid‐19 vaccine Canada Brian J Ward, et al. g/content/10.1101/2020 NCT04450004 CoVLP vaccine three dose levels Disease Produced in Plants Trial .11.04.20226282v1 unadjuvanted or adjuvanted with either CpG 1018 or AS03 To evaluate the efficacy and An open‐label, randomized trial of the https://www.sciencedir E‐Clinical safety in patients with combination of IFN‐κ plus TFF2 with ect.com/science/article/ ChiCTR2000030 27 October 2020 Medicine RCT China Weihui Fu, et al. IFN‐κ plus TFF2 moderate COVID‐19 f the standard care in the treatment of pii/S2589537020302911 262 (Lancet) combination of IFN‐κ plus patients with moderate COVID‐19 ?via%3Dihub TFF2 Safety and efficacy of inhaled nebulised https://www.thelancet.c The Lancet interferon beta‐1a (SNG001) for om/journals/lanres/artic 2020‐001023‐ Efficacy and safety of inhaled 12‐Nov‐20 Respiratory treatment of SARS‐CoV‐2 infection: a RCT UK Monk et al. le/PIIS2213‐ 14, INF‐beta 1a nebulised interferon beta‐1a Medicine randomised, double‐blind, placebo‐ 2600(20)30511‐ NCT04385095 controlled, phase 2 trial 7/fulltext Determine whether Fluvoxamine vs Placebo and Clinical fluvoxamine, given during https://jamanetwork.co Deterioration in Outpatients With mild COVID‐19 illness, 12‐Nov‐20 JAMA RCT USA Lenze et al. m/journals/jama/article‐ NCT04342663 Fluvoxamine Symptomatic COVID‐19A Randomized prevents clinical deterioration abstract/2773108 Clinical Trial and decreases the severity of disease

Antiviral effect of high‐dose ivermectin in https://papers.ssrn.com Does ivermectin reduce the Preprint The Lancet adults with COVID‐19: a pilot randomised, RCT Argentina Krolewiecki et al. /sol3/papers.cfm?abstra NCT004381884 Ivermectin viral load? controlled, open label, multicentre trial ct_id=3714649

Efficacy of Convalescent Plasma Therapy https://www.medrxiv.or To compare the efficacy and compared to Fresh Frozen Plasma in g/content/10.1101/2020 safety of convalescent plasma 27‐Oct MedRxiv RCT India Bajpai et al. NCT04346446 Convalescent plasma Severely ill COVID‐19 Patients: A Pilot .10.25.20219337v1.full.p with fresh frozen plasma (FFP) Randomized Controlled Trial. df in severe COVID‐19 patients

To evaluate the efficacy and https://www.medrxiv.or A placebo‐controlled double blind trial of Dubée et al. for the safety of hydroxychloroquine g/content/10.1101/2020 21‐Oct MedRxiv hydroxychloroquine in mild‐to‐moderate RCT France HYCOVID study NCT04325893 Hydroxychloroquine in adult patients with mild‐to‐ .10.19.20214940v1.full.p COVID‐19 group moderate COVID‐19 at risk of df worsening. To evaluate whether early https://www.medrxiv.or Early use of nitazoxanide in mild Covid‐19 nitazoxanide therapy would g/content/10.1101/2020 23‐Oct MedRxiv disease: randomized, placebo controlled RCT Brazil Rocco et al. NCT04552483 Nitazoxanide be effective in accelerating .10.21.20217208v1.full.p trial symptom resolution in df patients with mild COVID‐19. To test the combinational Controlled randomized clinical trial on https://www.medrxiv.or therapy of Ivermectin and using Ivermectin with Doxycycline for g/content/10.1101/2020 Ivermectin + 27‐Oct MedRxiv RCT Iraq Hashim et al. NCT04591600 Doxycycline in treating COVID‐ treating COVID‐19 patients in Baghdad, .10.26.20219345v1.full.p Doxycycline 19 patients at different stages Iraq df of the disease. To assess the efficacy and Treatment with human umbilical cord‐ https://www.medrxiv.or safety of human umbilical derived mesenchymal stem cells for human umbilical cord‐ g/content/10.1101/2020 cord‐mesenchymal stem cells 21‐Oct MedRxiv COVID‐19 patients with lung damage: a RCT China Shi et el. NCT04288102 derived mesenchymal .10.15.20213553v2.full.p (UC‐MSCs) to treat severe randomised, double‐blind, placebo‐ stem cells df COVID‐19 patients with lung controlled phase 2 trial damage. To determine safety and Umbilical Cord Mesenchymal Stem Cells https://papers.ssrn.com human umbilical cord‐ explore efficacy of Umbilical 26‐Oct Lancet pre‐print for COVID‐19 ARDS: A Double Blind, RCT USA Lanzoni et al. /sol3/papers.cfm?abstra NCT04355728 derived mesenchymal Cord (UC)‐MSC infusions in Phase 1/2a, Randomized Controlled Trial ct_id=3696875 stem cells COVID‐19 ARDS.

To determine whether https://academic.oup.co Sofosbuvir/daclatasvir regimens for the sofosbuvir/daclatasvir‐based J Antimicrob Meta‐ m/jac/advance‐ 01‐Nov treatment of COVID‐19: an individual UK/Iran Simmons et al. N/A sofosbuvir/daclatasvir regimens improve clinical Chemother analysis article/doi/10.1093/jac/ patient data meta‐analysis outcomes of patients with dkaa418/5924537 moderate or severe COVID‐19.

To evaluate the efficacy and https://papers.ssrn.com Phase 3 Trial of Coronavir (Favipiravir) in safety of favipiravir for 26‐Oct Lancet pre‐print RCT Russia Ruzhentsova et al. /sol3/papers.cfm?abstra NCT04501783 Favipiravir Patients with Mild to Moderate COVID‐19 treatment of mild to ct_id=3696907 moderate COVID‐19

Treatment of Coronavirus Disease 2019 https://www.sciencedir Efficacy of COVID‐19 Imunopatholog Patients with Convalescent Plasma ect.com/science/article/ convalescent plasma 01‐Nov‐20 y and infectious RCT USA Salazar et al. Convalescent plasma Reveals a Signal of Significantly pii/S0002944020303709 transfusion for severe and/or diseases Decreased Mortality ?via%3Dihub critical COVID‐19.

https://www.nejm.org/d Efficacy of Tocilizumab in Patients Does tocilizumab prevent 21‐Oct‐20 NEJM RCT USA Stone et al. oi/pdf/10.1056/NEJMoa NCT04356937 Tocilizumab Hospitalized with Covid‐19 intubation or death? 2028836

To determine whether Effect of Tocilizumab vs Usual Care in https://jamanetwork.co tocilizumab (TCZ) improves JAMA Internal Adults Hospitalized With COVID‐19 and m/journals/jamainternal 20‐Oct‐20 RCT France Hermine et al. NCT04331808 Tocilizumab outcomes of patients Medicine Moderate or Severe Pneumonia: A medicine/fullarticle/277 hospitalized with moderate‐to‐ Randomized Clinical Trial 2187 severe COVID‐19 pneumonia

Effect of Tocilizumab vs Standard Care on https://jamanetwork.co NCT04346355; JAMA Internal Clinical Worsening in Patients m/journals/jamainternal EudraCT To evaluate the effect of early 20‐Oct‐20 RCT Italy Salvarani et al. Tocilizumab Medicine Hospitalized With COVID‐19 PneumoniaA medicine/fullarticle/277 Identifier: 2020‐ tocilizumab administration Randomized Clinical Trial 2186 001386‐37.

International Journal of Randomize https://pharmascope.or To evaluate the efficacy of Efficacy of umifenovir in the treatment of 01‐Oct‐20 Research in d clinical Kyrgizstan Yethindra et al. g/ijrps/article/view/283 NA Umifenovir umifenovir in mild and mild and moderate covid‐19 patients Pharmaceutical study 9/6116 moderate COVID‐19 patients Sciences

To evaluate the efficacy of https://www.nejm.org/d Remdesivir for the Treatment of Covid‐19 John H. Beigel, et remdesivir in shortening time 8 October 2020 NEJM RCT USA oi/10.1056/NEJMoa2007 NCT04280705 Remdesivir — Final Repor al. to recovery in hospitalized 764 COVID‐19 patients.

Safety and immunogenicity of an https://www.sciencedir Phase 1/2 To assess the safety and inactivated SARS‐CoV‐2 vaccine, BBIBP‐ ect.com/science/article/ ChiCTR2000032 15 October 2020 Lancet vaccine China Shengli Xia, et al. BBIBP‐CorV immunogenicity of an CorV: a randomised, double‐blind, pii/S1473309920308318 459. trial inactivated SARS CoV2 vaccine placebo‐controlled, phase 1/2 trial ?via%3Dihub

Lopinavir/ritonavir, https://www.medrxiv.or Are repurposed andiviral Repurposed antiviral drugs for COVID‐19 Internation Hongchao Pan, et ISRCTN8397115 remdesivir, 15 October 2020 MedRiXV RCT g/content/10.1101/2020 drugs effective in treating COV –interim WHO SOLIDARITY trial results al al. 1 hydroxychloroquine, .10.15.20209817v1 ID19? interferon To assess the safety and dose response through reduction of https://www.nejm.org/d SARS‐CoV‐2 Neutralizing Antibody LY‐ Phase 2 Monoclonal antibody, viral load of monoclonal 28 October 2020 NEJM USA Peter Chen, et al. oi/10.1056/NEJMoa2029 NCT04427501 CoV555 in Outpatients with Covid‐19 RCT LY‐CoV555 antibody LY‐CoV555 in 849 patients with mild or moderate COVID‐19 To assess if a simple incentive to self‐prone for a maximum Self‐Proning in COVID‐19 Patients on Low‐ https://papers.ssrn.com Switzerlan SNCTP00000371 of 12 h per day would 21 October 2020 Lancet preprint Flow Oxygen Therapy: A Cluster RCT Aileen Kharat, et al. /sol3/papers.cfm?abstra Self‐proning d 8 decrease oxygen needs in Randomised Controlled Trial ct_id=3692538 patients admitted for COVID‐ 19 pneumonia International Interim analysis of an open‐label To assess if nasal irrigation can https://onlinelibrary.wil 11 September Forum of randomized controlled trial evaluating Kyle S. Kimura, et reduce symptoms and viral RCT USA ey.com/doi/10.1002/alr. NA Nasal irrigations 2020 Allergy and nasal irrigations in non‐hospitalized al. shedding in mild and 22703 Rhinology patients with coronavirus disease 2019 moderate COVID‐19 patients

To assess the safety and https://www.medrxiv.or efficacy of tocilizumab in Tocilizumab in nonventilated patients Preprint MedRiXV RCT USA Carlos Salama, et al. g/content/10.1101/2020 NCT04372186 Tocilizumab patients hospitalized and non‐ hospitalized with Covid‐19 pneumonia .10.21.20210203v1 ventilated with Covid‐19 pneumonia. The use of intravenous immunoglobulin https://bmcinfectdis.bio To evaluate the efficacy of gamma for the treatment of severe BMC Infectious Naser Gharebaghi, medcentral.com/articles IRCT202005010 Immunoglobulin intravenous immunoglobulin 21 October 2020 coronavirus disease 2019: a randomized RCT Iran Diseases et al. /10.1186/s12879‐020‐ 47259N1 gamma (IVIg) in patients with severe placebo‐controlled double‐blind clinical 05507‐4 COVID‐19 infection. trial Anti‐C5a antibody IFX‐1 (vilobelimab) https://www.thelancet.c Phase 2 study to explore the treatment versus best supportive care for 28 September Netherland Alexander P J Vlaar, om/action/showPdf?pii= potential benefit and safety of Lancet patients with severe COVID‐19 RCT NCT04333420 Vilobelimab 2020 s et al. S2665‐ IFX‐1 (vilobelimab) in patients (PANAMO): an exploratory, open‐label, 9913%2820%2930341‐6 with severe COVID‐19. phase 2 randomised controlled trial

Is the SARS CoV‐2 mRNA 1273 Vaccine https://www.nejm.org/d 29 September Safety and Immunogenicity of SARS‐CoV‐ Evan J. Anderson, et safe and well tolerated in NEJM trial Phase USA oi/full/10.1056/NEJMoa NCT04283461 mRNA‐1273 vaccine 2020 2 mRNA‐1273 Vaccine in Older Adults al. older adults and does it ellicit 1 2028436 an immune response?

30 September Vaccine https://www.nature.co Does the BNT162b1 vaccine COVID‐19 vaccine BNT162b1 elicits 2020 ‐pre‐ Nature trial Phase Germany Ugur Sahin, et al. m/articles/s41586‐020‐ NCT04380701 BNT162b1 vaccine elicit both antibody and T‐cell human antibody and TH1 T‐cell responses approved 1 and 2 2814‐7 response in healthy adults?

To evaluate the efficacy and https://assets.researchs safety of recombinant super‐ Engineered interferon alpha effectively quare.com/files/rs‐ Research ChiCTR2000029 Engineered interferon compound interferon versus Preprint improves clinical outcomes of COVID‐19 RCT China Chuan Li, et al. 65224/v1/22886bf0‐ Square 638 alpha traditional interferon alpha in patients ce06‐4d42‐aeb6‐ patients with moderate to c73ebb7c2003.pdf severe COVID‐19 https://www.sciencedir To evaluate the efficacy and International Interferonβ‐1b in treatment of severe Hamid Rahmani, et ect.com/science/article/ IRCT201002280 safety of interferon (IFN) β‐1b 24 August 2020 Immunopharma RCT Iran Interferon β‐1b COVID‐19: A randomized clinical trial al. pii/S1567576920323304 03449N27 in the treatment of patients cology ?via%3Dihub with severe COVID‐19 To evaluate the efficacy of Efficacy and Safety of https://jamanetwork.co hydroxychloroquine to 30 September Hydroxychloroquine vs Placebo for Pre‐ Benjamin S Abella, m/journals/jamainternal prevent transmission of SARS‐ JAMA RCT USA NCT04329923 Hydroxychloroquine 2020 exposure SARS‐CoV‐2 Prophylaxis Among et al. medicine/fullarticle/277 CoV‐2 in hospital‐based HCWs Health Care Workers 1265 with exposure to patients with COVID‐19 using a pre‐ Internation Drug treatments for covid‐19: living To compare the effects of Systematic al Reed AC https://www.bmj.com/c 4 September 2020 BMJ systematic review and NA All treatments treatments for coronavirus review collaborati Siemieniuk, et al. ontent/370/bmj.m2980 network meta‐analysis disease 2019 (covid‐19). on To compare the rate of clinical improvement among patients Effect of remdesivir on patients with https://www.ncbi.nlm.ni Meta‐ with COVID‐19 who received 5‐ 15‐Oct Virus Research COVID‐19: A network meta‐analysis of USA, Japan Yokoyama et al. h.gov/pmc/articles/PMC N/A Remdesivir analysis day course of remdesivir randomized control trials 7437510/pdf/main.pdf versus 10‐day course of remdesivir versus standard To investigate the safety and https://www.medrxiv.or immunogenicity of an An in‐depth investigation of the safety Phase 1 g/content/10.1101/2020 inactivated viral vaccine in 06‐Sep MedRxiv and immunogenicity of an inactivated 2 China Pu et el. NCT04412538 Vaccine RCT .09.27.20189548v1.full.p immunized individuals in a SARS‐CoV‐2 vaccine df phase I trial, especially focusing on safety with regard Clearing the fog: Is Hydroxychloroquine https://www.medrxiv.or To assess the efficacy of HCQ effective in reducing Corona virus disease‐ Mehmood Kamran g/content/10.1101/2020 11‐Oct MedRxiv RCT Pakistan NCT04491994 Hydroxychloroquine in reducing disease 2019 progression: A randomized et al. .07.30.20165365v2.full.p progression in mild COVID‐19 controlled trial df

Lopinavir–ritonavir in patients admitted https://www.thelancet.c Whether lopinavir–ritonavir ISRCTN to hospital with COVID‐19 (RECOVERY): a Horby et al. om/action/showPdf?pii= improves outcomes in 05‐Oct‐20 The Lancet RCT UK 50189673, lopinavir/ritonavir randomised, controlled, open‐label, (RECOVERY GROUP) S0140‐ patients admitted to hospital NCT04381936 platform trial 6736%2820%2932013‐4 with COVID‐19

An open‐label, randomized trial of the https://www.sciencedir EClinicalMedici combination of IFN‐kappa plus TFF2 with ect.com/science/article/ ChiCTR2000030 Efficacy and safety of IFN‐κ 20‐Sep‐20 RCT China Fu et al. IFN‐κ , TFF2 ne standard care in the treatment of pii/S2589537020302911 262 and TFF2 in COVID patients. patients with moderate COVID‐19 ?via%3Dihub Vaccine: non‐ Safety and immunogenicity of the https://www.medrxiv.or replicating adenovirus Ad26.COV2.S COVID‐19 vaccine Netherland To evaluate the efficacy of a Phase 1/2a g/content/10.1101/2020 26 based vector 25‐Sep MedRxiv candidate: interim results of a phase s, Belgium, Sadoff et al. NCT04436276 single vaccination of 5x1010 vp RCT .09.23.20199604v1.full.p expressing the 1/2a, double‐blind, randomized, placebo‐ USA of Ad26.COV2.S df stabilized pre‐fusion controlled trial spike protein of SARS‐ To determine the https://www.medrxiv.or effectiveness of Hydroxychloroquine as pre‐exposure g/content/10.1101/2020 hydroxychloroquine as pre‐ 21‐Sep MedRxiv prophylaxis for COVID‐19 in healthcare RCT USA Rajasingham et al. NCT04328467 Hydroxychloroquine .09.18.20197327v1.full.p exposure prophylaxis in workers: a randomized trial df healthcare workers at high‐ risk of SARS‐CoV‐2 exposure Treatment with an Anti‐CK2 Synthetic https://www.medrxiv.or Peptide Improves Clinical 3 Response in IG/CIGB300I/CV To explore safety and efficacy g/content/10.1101/2020 Anti‐CK2 Synthetic 22‐Sep MedRxiv Covid‐19 Patients with Pneumonia. A RCT Cuba Cruz et al. /2001, ATENEA‐ of CIGB‐325, an anti‐CK2 .09.03.20187112v2.full.p Peptide, CIGB‐325 Randomized and 4 Controlled Clinical Co‐300 trial peptide, in COVID‐19 patients. df Trial To compare the rate of clinical https://www.sciencedir improvement among patients Effect of remdesivir on patients with Meta‐ Yujiro Yokoyama et ect.com/science/article/ with COVID‐19 who received 5‐ 15‐Oct Virus Research COVID‐19: A network meta‐analysis of USA, Japan N/A Remdesivir analysis al. pii/S0168170220310443 day course of remdesivir randomized control trials ?via%3Dihub versus 10‐day course of remdesivir versus standard https://academic.oup.co Clinical NCT04292899 Remdesivir for Severe COVID‐19 versus a RCT vs Susan A. Olender, m/cid/advance‐ Efficacy of remdesivir in 24 July 2020 Infectious USA and Remdesivir Cohort Receiving Standard of Care cohort et al. article/doi/10.1093/cid/ COVID19 patients Diseases EUPAS34303 ciaa1041/5876045

Assess the efficacy of Antimicrobial A prospective, randomized, open‐label https://aac.asm.org/con favipiravir in asymptomatic or 17 November Agents trial of early versus late favipiravir in RCT Japan Yohei Doi, et al. tent/early/2020/09/16/ jRCTs04119012 Favipiravir mild COVID19 patients in viral 2020 Chemotherapy hospitalized patients with COVID‐19 AAC.01897‐20 0 clearance, and resolution of symptoms

Favipiravir versus other antiviral or Systematic https://virologyj.biomed To evaluate the efcacy and standard of care for COVID‐19 treatment: review & Dhan Bahadur central.com/articles/10. 24‐Sep Virology Journal Nepal N/A Favipiravir safety of the drug Favipiravir a rapid systematic review and meta‐ meta‐ Shrestha et al. 1186/s12985‐020‐01412‐ as a treatment for COVID‐19. analysis analysis z

To compare therapeutic Therapeutic versus prophylactic https://www.thrombosis Anna Cristina enoxaparin treatment to 20 September Thrombosis anticoagulation for severe COVID‐19: A research.com/article/S0 REBEC RBR‐ Enoxaparin, RCT Brazil Bertoldi Lemos, et standard prophylactic 2020 Research randomized phase II clinical trial 049‐3848(20)30530‐ 949z6v anticoagulants al. anticoagulant treatment in (HESACOVID) 2/fulltext#%20 severe COVID19 Treatment of COVID‐19 Patients with To evaluate the efficacy and https://academic.oup.co Clinical Prolonged Post‐Symptomatic Viral safety of leflunomide to treat m/cid/advance‐ ChiCTR Preprint Infectious Shedding with Leflunomide ‐‐ a Single‐ RCT China Wang, et al Leflunomide COVID‐19 patients with article/doi/10.1093/cid/ 2000030058 Diseases Center, Randomized, Controlled Clinical prolonged post‐symptomatic ciaa1417/5909448 Trial viral shedding. Effect of hydroxychloroquine with or https://www.clinicalmicr To assess the effect of Systematic Clinical without azithromycin on the mortality of France, obiologyandinfection.co Chloroquine, chloroquine and Review and Thibault Fiolet, et 26 August 2020 Microbiology coronavirus disease 2019 (COVID‐19) Switzerlan m/article/S1198‐ NA hydroxychloroquine, hydroxychloroquine with or Meta‐ al. and Infection patients: a systematic review and meta‐ d 743X(20)30505‐ azithromycin without azithromycin on the analysis analysis X/fulltext mortality of COVID‐19 patients To evaluate and compare Efficacy of commercial mouth‐rinses on Chaminda https://www.medrxiv.or different commercial Preprint MedRxIV SARS‐CoV‐2 viral load in saliva: RCT Singapore Jayampath g/content/10.1101/2020 NA Mouth wash moutwash solutions and their Randomized Control Trial in Singapore Seneviratne, et al. .09.14.20186494v1 effect on reducing salivary viral load Evaluate the safety and Early Anti‐SARS‐CoV‐2 Convalescent https://www.medrxiv.or efficacy of convalescent María Elvira Preprint MedRxIV Plasma in Patients Admitted for COVID‐ RCT Chile g/content/10.1101/2020 NCT04375098 Covalescent Plasma plasma and compare an early Balcells, et al. 19: A Randomized Phase II Clinical Trial .09.17.20196212v1 vs deferred treatement strategy Evaluate the efficacy of bromhexine in intensive care Effect of bromhexine on clinical outcomes https://bi.tbzmed.ac.ir/ IRCT202003117 unit (ICU) admission, 19 July 2020 Bioimpacts and mortality in COVID‐19 patients: A RCT Iran Khalil Ansarin Bromhexine Article/bi‐23240 046797N4 mechanical ventilation, and randomized clinical trial mortality in patients with COVID‐19. https://www.tandfonlin Identify studies pertaining to Expert Review The effect of antivirals on COVID‐19: a Systematic Hussain et e.com/doi/abs/10.1080/ antivirals in COVID‐19 patients 12‐Sep‐20 of Anti‐Infective UK NA Antivirals systematic review review al. 14787210.2021.1823832 and review the clinical Therapy ?journalCode=ierz20 outcomes

Double‐blind, randomized, placebo‐ https://academic.oup.co To determine whether NAC in Clinical 23 September controlled trial with N‐acetylcysteine for Julio Cesar Garcia m/cid/advance‐ high doses can avoid Infectious RCT Brazil 2020 treatment of severe acute respiratory de Alencar, et al. article/doi/10.1093/cid/ respiratory failure in patients Diseases syndrome caused by COVID‐19 ciaa1443/5910353 with Covid‐19.

Intravenous methylprednisolone pulse as https://erj.ersjournals.c European Is methylprednisolone a treatment for hospitalised severe om/content/early/2020/ IRCT202004040 17‐Sep‐20 Respiratory RCT Iran Edalatifard et al. Methylprednisolone effective in treatment of COVID‐19 patients: results from a 09/09/13993003.02808‐ 46947N1 Journal COVID‐19 patients? randomised controlled clinical trial 2020

Interventions for treatment of COVID‐19: https://journals.plos.org A living systematic review with meta‐ Meta‐ /plosmedicine/article?id Effects of all treatment 17‐Sep‐20 Plos Medicine Denmark Juul et al. NA NA analyses and trial sequential analyses analysis =10.1371/journal.pmed. interventions for COVID‐19 (The LIVING Project) 1003293

Safety and immunogenicity of an rAd26 https://www.sciencedir and rAd5 vector‐based heterologous NCT04436471 Safety and immunogenicity of ect.com/science/article/ 04‐Sep‐20 The Lancet prime‐boost COVID‐19 vaccine in two CT Russia Logunov et al. and vaccine two formulations (frozen and pii/S0140673620318663 formulations: two open, non‐randomised NCT04437875 lyophilised) of vaccine ?via%3Dihub phase 1/2 studies from Russia

International https://www.sciencedir Safety and effectiveness of azithromycin Can therapy with HCQ+AZM Journal of ect.com/science/article/ 01‐Oct‐20 in patients with COVID‐19: An open‐label RCT Iran Sekhavati et al. NA azithromycine reduce the hospital length of Antimicrobial pii/S0924857920303411 randomised trial stay in COVID‐19 patients? Agents ?via%3Dihub

Effect of Recombinant Human Do increased peripheral blood https://jamanetwork.co Granulocyte Colony–Stimulating Factor leukocyte and lymphocyte cell m/journals/jamainternal ChiCTR2000030 10‐Sep‐20 JAMA for Patients With Coronavirus Disease RCT China Cheng et al. G‐CSF counts lead to clinical medicine/fullarticle/277 007 2019 (COVID‐19) and Lymphopenia: A improvement in patients with 0680 Randomized Clinical Trial COVID‐19? Azithromycin in addition to standard of https://www.thelancet.c care versus standard of care alone in the Would azithromycine improve om/action/showPdf?pii= 04‐Sep‐20 The Lancet treatment of patients admitted to the RCT Brazil Furtado et al. NCT04321278 azithromycine clinical outcomes to COVID‐19 S0140‐ hospital with severe COVID‐19 in Brazil patiets? 6736%2820%2931862‐6 (COALITION II): a randomised clinical trial Is the use of CQ or HCQ Journal effective and safe in reducing Chloroquine and Hydroxychloroquine for https://link.springer.co Genenral Systematic Arunmozhimaran Chloroquine, mortality and improving the 03‐Sep‐20 the Treatment of COVID‐19: a Systematic India m/article/10.1007/s116 NA Internal review Elavarasi, et al. hydroxychloroquine clinical course, fever Review and Meta‐analysis 06‐020‐06146‐w Medicine remission, and virologic clearance in COVID‐19 Diabetes & Metabolic No benefit of hydroxychloroquine in https://www.sciencedir November ‐ Syndrome: COVID‐19: Results of Systematic Review Systematic ect.com/science/article/ Is HCQ effective in milde to India Pathak et al. NA hydroxychloroquine December 2020 Clinical and Meta‐Analysis of Randomized review pii/S1871402120303362 moderate COVID‐19 patients? Research & Controlled Trials" ?via%3Dihub Reviews Naunyn‐ Hydroxychloroquine use and progression https://link.springer.co Schmiedeberg's Systematic Benefits and harms of HCQ in 06‐Sep‐20 or prognosis of COVID‐19: a systematic China Zang et al m/article/10.1007%2Fs0 NA hydroxychloroquine Archives of review COVID‐19 patients review and meta‐analysis 0210‐020‐01964‐5 Pharmacology https://jamanetwork.co To determine whether Effect of Dexamethasone on Days Alive m/journals/jama/fullarti intravenous dexamethasone and Ventilator‐Free in Patients With Bruno M. Tomazini, cle/2770277?utm_camp increases the number of 02‐Sep‐20 JAMA Moderate or Severe Acute Respiratory RCT Brazil NCT04327401 Dexamethasone et al. aign=articlePDF&utm_m ventilator‐free days among Distress Syndrome and COVID‐19 The edium=articlePDFlink&u patients with COVID‐ CoDEX Randomized Clinical Trial tm source=articlePDF& 19–associated ARDS. https://jamanetwork.co To estimate the association Association Between Administration of Internation m/journals/jama/fullarti PROSPERO between administration of Systemic Corticosteroids and Mortality Meta‐ al cle/2770279?utm_camp database 02‐Sep‐20 JAMA Jonathan A.C., et al. Corticosteroids corticosteroids compared with Among Critically Ill Patients With COVID‐ analysis Collaborati aign=articlePDF&utm_m (CRD420201972 usual care or placebo and 28‐ 19 ‐ A Meta‐analysis on edium=articlePDFlink&u 42) day all‐cause mortality. tm source=articlePDF& https://jamanetwork.co Does low‐dose hydrocortisone Effect of Hydrocortisone on 21‐Day m/journals/jama/fullarti decrease treatment failure in Mortality or Respiratory Support Among Pierre‐François cle/2770276?utm_camp 02‐Sep‐20 JAMA RCT France NCT02517489 Hydrocortisone patients with COVID‐ Critically Ill Patients With COVID‐19 ‐ A Dequin, et al. aign=articlePDF&utm_m 19–related acute respiratory Randomized Clinical Trial edium=articlePDFlink&u failure? tm source=articlePDF& https://jamanetwork.co Effect of Hydrocortisone on Mortality and m/journals/jama/fullarti To determine whether Organ Support in Patients With Severe Derek C. Angus, et cle/2770278?utm_camp hydrocortisone improves 02‐Sep‐20 JAMA COVID‐19 The REMAP‐CAP COVID‐19 RCT UK NCT02735707 Hydrocortisone al. aign=articlePDF&utm_m outcome for patients Corticosteroid Domain Randomized edium=articlePDFlink&u with severe COVID‐19. Clinical Trial tm source=articlePDF& Convalescent plasma in the management Anup Agarwal et al. To assess the effectiveness of of moderate COVID‐19 in India: An open‐ https://www.bmj.com/c CTRI/2020/04/0 12 October 2020 BMJ RCT India and PLACID Convalescent plasma Convalescent plasma for the label parallel‐arm phase II multicentre ontent/371/bmj.m3939 24775 Collaborators treatment of COVID‐19 randomized controlled trial (PLACID Trial) To demonstrate the efficacy https://www.medrxiv.or and safety of Convalescent Convalescent Plasma for COVID‐19: A Avendaño‐Solà et g/content/10.1101/2020 Plasma used to prevent 01‐Sep MedRxiv RCT Spain NCT04345523 Convalescent plasma multicenter, randomized clinical trial al. .08.26.20182444v3.full.p progression to severe disease df or death in hospitalized patients with earlier forms of Gargling with 1% https://www.medrxiv.or To assess the ability of regular Early viral clearance among COVID‐19 povidone‐iodine Nurul Azmawati g/content/10.1101/2020 gargling to eliminate SARS‐ 09‐Sep MedRxiv patients when gargling with Povidone‐ RCT Malaysia NCT04410159 (Betadine®), essential Mohamed et al. .09.07.20180448v1.full.p CoV‐2 in the oropharynx and Iodine and Essential oils ‐ a clinical trial. oils (Listerine®) or tap df nasopharynx. water

https://www.medrxiv.or To investigate whether Tocilizumab in Hospitalized Patients With g/content/10.1101/2020 tocilizumab has clinical benefit 12/09/2020 MedRxiv RCT USA Rosas et al. NCT04320615 Tocilizumab COVID‐19 Pneumonia .08.27.20183442v2.full.p in hospitalized patients with df severe COVID‐19 pneumonia.

https://www.sciencedir Efficacy and safety of triazavirin therapy ect.com/science/article/ ChiCTR2000030 To assess the efficacy of 08‐Sep Engineering for coronavirus disease 2019: A pilot RCT China Wu et al. Triazavirin pii/S2095809920302411 0001 Triazavirin (TZV) for Covid‐19 randomized controlled trial ?via%3Dihub Patient‐Reported Health Outcomes After To evaluate the efficacy of https://assets.researchs Treatment of COVID‐19 with Nebulized treatment with intravenous quare.com/files/rs‐ BMC Infectious and/or Intravenous Neutral Electrolyzed Delgado‐Enciso et neutral electrolyzed and/or nebulized neutral 10‐Sep RCT Cuba 68403/v1/e14a5067‐ RPCEC00000309 Diseases. Saline Combined with Usual Medical Care al. saline electrolyzed saline combined cd36‐4094‐9c29‐ Versus Usual Medical care alone: A with usual medical care versus 4bb66ac46805.pdf Randomized, Open‐Label, Controlled usual medical care alone, in https://www.sciencedir Computers in Prediction of respiratory decompensation ect.com/science/article/ 01‐Sep‐20 Biology and in Covid‐19 patients using machine RCT USA Burdick et al. NCT04390516 NA NA pii/S0010482520302845 Medicine learning: The READY trial ?via%3Dihub

Journal of Effectiveness of remdesivir for the https://onlinelibrary.wil Remdesivir and its clinical 19‐Aug‐20 Medical treatment of hospitalized Covid‐19 Review China Jiang et al. ey.com/doi/abs/10.1002 NA Remdesivir effect Virology persons: a network meta‐analysis /jmv.26443

Sofosbuvir and daclatasvir compared with https://academic.oup.co Journal of standard of care in the treatment of m/jac/advance‐ IS sofosbuvir and dalatasvir 19‐Aug‐20 Antimicrobial patients admitted to hospital with RCT Iran Sadeghi et al. IRCT202001280 sofosbuvir/daclatasvir article/doi/10.1093/jac/ effective in COVID patients? Chemotherapy moderate or severe coronavirus infection 46294N2 dkaa334/5889948 (COVID‐19): a randomized controlled trial Are human umbilical cord https://stemcellres.bio Stem Cell Treatment of severe COVID‐19 with umbilical cord mesenchymal stem cell medcentral.com/articles ChiCTR2000031 18‐Aug‐20 Research & human umbilical cord mesenchymal stem RCT China Shu et al. mesenchymal stem infusion effective and safe for /10.1186/s13287‐020‐ 494 Therapy cells cells the treatment of severe 01875‐5 COVID? "Effect of Calcifediol Treatment and best Journal of Evaluate the effect of Available Therapy versus best Available https://www.sciencedir Steroid calcifediol on ICU admission Therapy on Intensive Care Unit Admission Marta Entrenas ect.com/science/article/ October Biochemistry RCT Spain NCT04366908 Calcifediol and mortality among patients and Mortality Among Patients Castillo, et al. pii/S0960076020302764 and Molecular hospitalized for COVID‐19 Hospitalized for COVID‐19: A Pilot ?via%3Dihub Biology Randomized Clinical study Effect of an Inactivated Vaccine Against Vaccine ‐ https://jamanetwork.co To assess the safety and SARS‐CoV‐2 on Safety and ChiCTR2000031 13 August 2020 JAMA Phase I and China Shengli Xia, et al. m/journals/jama/fullarti Inactivated vaccine immunogenicity of this whole Immunogenicity Outcomes Interim 809 II cle/2769612 virus inactivated vaccine Analysis of 2 Randomized Clinical Trials Effect of Remdesivir vs Standard Care on https://jamanetwork.co Christoph D. Effect of remdesivir in patients 21 August 2020 JAMA Clinical Status at 11 Days in Patients With RCT USA m/journals/jama/fullarti NCT04292730 Remdesivir Spinner, et al. with moderate COVID19 Moderate COVID‐19 cle/2769871

Internation Drug treatments for covid‐19: living Systematic al Reed AC https://www.bmj.com/c Living systematic review and 30 July 2020 BMJ systematic review and network meta‐ NA All treatments Review Collaborati Siemieniuk, et al. ontent/370/bmj.m2980 network meta‐analysis analysis on

https://www.medrxiv.or To assess the safety and Vaccine: RNA vaccines RNA‐Based COVID‐19 Vaccine BNT162b2 USA/ g/content/10.1101/2020 immunogenicity of varying 28‐Aug MedRXiv RCT Walsh et al. NCT04368728 BNT162b1 and Selected for a Pivotal Efficacy Study Germany .08.17.20176651v2.full.p dose levels of vaccines BNT162b2 df BNT162b1 and BNT162b2.

Methylprednisolone as Adjunctive https://academic.oup.co Clinical Therapy for Patients Hospitalized With Christiane Maria Assess the efficacy of short‐ m/cid/advance‐ 12 August 2020 Infectious COVID‐19 (Metcovid): A Randomised, RCT Brazil Prado Jeronimo, et NCT04343729 Methylprednisolone term methylprednisolone in article/doi/10.1093/cid/ Diseases Double‐Blind, Phase IIb, Placebo‐ al. patients with COVID‐19 ciaa1177/5891816 Controlled Trial Assess the efficacy and safety AVIFAVIR for Treatment of Patients with https://academic.oup.co Clinical of favipiravir in moderate Moderate COVID‐19: Interim Results of a Andrey A. m/cid/advance‐ 09 August 2020 Infectious RCT Russia NCT04434248 Favipiravir COVID19 and select the Phase II/III Multicenter Randomized Ivashchenko, et al. article/doi/10.1093/cid/ Diseases optimal dosing regimen for Clinical Trial ciaa1176/5890024 further evaluation (Phase III). Efficacy of Novaferon and International SARS‐CoV‐2 Clearance in COVID‐19 https://www.sciencedir Novaferon + Journal of Patients with Novaferon Treatment: A ect.com/science/article/ ChiCTR2000029 Preprint China Fang Zheng, et al. Novaferon Lopinavir/ritonavir in Infectious Randomized, Open‐label, Parallel Group pii/S120197122030597X 496 moderate and severe Diseases Trial ?via%3Dihub COVID19.

Telmisartan for treatment of Covid‐19 https://www.medrxiv.or Assess the anti‐inflammatory Mariano Duarte, et Preprint medRxiv patients: an open randomized clinical RCT Argentina g/content/10.1101/2020 NCT04355936 Telmisartan effect of telmisartan in COVID‐ al. trial. Preliminary report. .08.04.20167205v2 19 patients

Auxora versus standard of care for the https://ccforum.biomed Safety and tolerability of treatment of severe or critical COVID‐19 central.com/articles/10. 14 August 2020 Critical Care RCT USA Joseph Miller, et al. NCT04345614. Auxora auxora in severe or critical pneumonia: results from a randomized 1186/s13054‐020‐03220‐ COVID‐19 controlled trial x

Immunogenicity and Safety of a SARS‐CoV‐ 2 Inactivated Vaccine in Healthy Adults Phase II https://www.medrxiv.or Is this SARS CoV 2 inactivated Preprint medRxiv Aged 18‐59 years: Report of the vaccine China Yanjun Zhang, et al. g/content/10.1101/2020 NCT04352608 Inactiviated Vaccine vaccine safe and well Randomized, Double‐blind, and Placebo‐ RCT .07.31.20161216v1 tolerated? controlled Phase 2 Clinical Trial

Beneficial effects of colchicine for https://www.medrxiv.or To evaluate the efficacy of moderate to severe COVID‐19: an interim Maria IF Lopes, et Preprint medRxiv RCT Brazil g/content/10.1101/2020 RBR‐8jyhxh Colchicine colcihcine in treating severe analysis of a randomized, double‐blinded, al. .08.06.20169573v2 and moderate COVID‐19 placebo controlled clinical trial

Assess the safety and Phase 1–2 Trial of a SARS‐CoV‐2 Phase I https://www.nejm.org/d NVX‐CoV2373; tolerability of the NVX‐ 2 September 2020 NEJM Recombinant Spike Protein Nanoparticle vaccine Australia Cheryl Keech, et al. oi/full/10.1056/NEJMoa NCT04368988 recombinant COV2373 recombinant vaccine Vaccine RCT 2026920 nanoparticle vaccine in healthy subjects.

Asses the efficacy of Hydroxychloroquine with or without https://www.nejm.org/d Alexandre B. hydroxychloroquine with and 23 July 2020 NEMJ Azithromycin in Mild‐to‐Moderate Covid‐ RCT Brazil oi/10.1056/NEJMoa2019 NCT04322123 Hydroxychloroquine Cavalcanti, et al. without azithromycin in mild 19 014 to moderate COVID19 Hydroxychloroquine, Tocilizumab, Journal of Systematic Review and Meta‐analysis of Viveksandeep https://onlinelibrary.wil Asses overall efficacy of Systematic Remdesivir, 6 July 2020 Medical Effectiveness of Treatment Options USA Thoguluva ey.com/doi/epdf/10.100 NA treatments that have been review convalescent plasma, Virology Against SARS‐CoV‐2 infection Chandrasekar, et al. 2/jmv.26302 studied thus far. steroids, lopinavir/ritonavir

Use of a humanized anti‐CD6 monoclonal https://www.medrxiv.or Is itolizumab a safe and Preprint medRxiv antibody (itolizumab) in elderly patients CT Cuba Yayquier Díaz, et al. g/content/10.1101/2020 RPCEC00000311 Itolizumab efficient treatment for COVID with moderate COVID‐19 .07.24.20153833v1 19 in elderley patients?

https://www.medrxiv.or Is bevacizumab a safe and Efficacy and tolerability of bevacizumab Preprint medRxiv CT China, Italy Jiaojiao Pang, et al g/content/10.1101/2020 NCT04275414 Bevacizumab efficient treatment for severe in patients with severe Covid ‐19 .07.26.20159756v1 COVID 19?

A clinical pilot study on the safety and To evaluate the efficacy and https://www.sciencedir EClinicalMedici efficacy of aerosol inhalation treatment China + ChiCTR2000030 IFN‐κ plus trefoil safety of intranasal inhalation 29 July 2020 CT Weihui et al. ect.com/science/article/ ne (Lancet) of IFN‐κ plus TFF2 in patients with USA 262 factor 2 of TFF2 and IFN‐κ protein for pii/S2589537020302224 moderate COVID‐19 SARS‐CoV‐2 infection

A Small‐Scale Medication of Leflunomide https://link.springer.co ChiCTR Is leflunomide effective in 21 July 2020 Virologica Sinica as a Treatment of COVID‐19 in an Open‐ CT China Hu et al. m/article/10.1007%2Fs1 leflunomide 2000030058 COVID‐19 patients? Label Blank‐Controlled Clinical Trial 2250‐020‐00258‐7

Safety and immunogenicity of the https://www.thelancet.c To assess the immunogenicity, Folegatti et al. on ChAdOx1 nCoV‐19 vaccine against SARS‐ om/journals/lancet/artic ISRCTN reactogenicity, and safety of behalf of the ChAdOx1 nCoV‐19 20‐Jul Lancet CoV‐2: a preliminary report of a phase RCT UK le/PIIS0140‐ 15281137; vaccination with ChAdOx1 Oxford COVID vaccine 1/2, single‐blind, randomised controlled 6736(20)31604‐ NCT04324606 nCoV‐19 in single‐dose and Vaccine Trial Group trial 4/fulltext two‐dose regimens. Phase 2 trial to further Immunogenicity and safety of a https://www.thelancet.c evaluate the immunogenicity recombinant adenovirus type‐5‐vectored adenovirus type‐5 om/action/showPdf?pii= and safety in a larger 20‐Jul Lancet COVID‐19 vaccine in healthy adults aged RCT China Feng‐Cai Zhu et al. NCT04341389 (Ad5)‐vectored COVID‐ S0140‐ population, and to determine 18 years or older: a randomised, double‐ 19 vaccine 6736%2820%2931605‐6 an appropriate dose for the blind, placebo‐controlled, phase 2 trial efficacy study To assess safety, tolerability, https://www.nature.co and immunogenicity of RNA Phase 1/2 study of COVID‐19 RNA vaccine Phase 1/2 USA/Germ RNA Vaccine 12 August 2020 Nature Mulligan et al. m/articles/s41586‐020‐ NCT04368728 Vaccine candidate in a dose BNT162b1 in adults trial any BNT162b1 2639‐4 escalation study among healthy adults. To complement previous https://www.medrxiv.or reported data by providing a Concurrent human antibody and TH1 NCT04380701, Phase 1/2 Germany/ g/content/10.1101/2020 RNA Vaccine detailed characterisation of 20‐Jul‐20 Medrxiv type T‐cell responses elicited by a COVID‐ Sahin et al. EudraCT: 2020‐ trial USA .07.17.20140533v1.full.p BNT162b1 antibody and T76 cell immune 19 RNA vaccine 001038‐36 df responses elicited by BNT162b1 vaccination.

https://www.nejm.org/d To evaluate the safety and An mRNA Vaccine against SARS‐CoV‐2 — Phase 1 14‐Jul NEMJ USA Jackson et al. oi/pdf/10.1056/NEJMoa NCT04283461 mRNA‐1273 vaccine immunogenicity of mRNA‐ Preliminary Report trial 2022483 1273 vaccine

To assess the safety and Effect of Hydroxychloroquine in Horby et al. https://www.nejm.org/d ISRCTN efficacy of Hospitalized Patients with COVID‐19: (RECOVERY 08‐Oct NEJM RCT UK oi/10.1056/NEJMoa2022 50189673, Hydroxychloroquine hydroxychloroquine in Preliminary results from a multi‐centre, Collaborative 926 NCT04381936 patients hospitalized with randomized, controlled trial. Group) COVID‐19 A Multicenter, randomized, open‐label, controlled trial to evaluate the efficacy RCT & https://www.medrxiv.or To evaluate HCQ efficacy and and tolerability of hydroxychloroquine retrospecti Cheng‐Pin Chen et g/content/10.1101/2020 tolerability in adult patients 10‐Jul Medrxiv Taiwan NCT04384380 Hydroxychloroquine and a retrospective study in adult ve cohort al. .07.08.20148841v1.full.p with mild to moderate COVID‐ patients with mild to moderate study df 19. Coronavirus disease 2019 (COVID‐19) To investigate whether Annals of Hydroxychloroquine in Nonhospitalized https://www.acpjournal hydroxychloroquine could 16‐Jul Internal Adults With Early COVID‐19 ‐ A RCT USA Skipper et al. s.org/doi/10.7326/M20‐ NCT04308668 Hydroxychloroquine reduce COVID‐19 severity in Medicine Randomized Trial 4207 adult outpatients Is early treatment with Hydroxychloroquine Alone or in hydroxychloroquine (HCQ) https://papers.ssrn.com Combination with Cobicistat‐Boosted Hydroxychloroquine, with our without Preprint Lancet RTC Spain Mitjà et al, /sol3/papers.cfm?abstra NCT04304053 Darunavir for Treatment of Mild COVID‐ Darunavir, Cobicistat cobicistat/darunavir more ct_id=3615997 19: A Cluster‐Randomized Clinical Trial efficacious than no‐treatment for outpatients with mild To assess the effcacy and https://assets.researchs A pragmatic randomized controlled trial safety of hydroxychloroquine quare.com/files/rs‐ reports the efficacy of Magnus Nakrem therapy on SARS‐CoV‐2 Preprint ResearchSquare RCT Norway 44055/v1/3fb11155‐ NCT04316377 Hydroxychloroquine hydroxychloroquine on coronavirus Lyngbakken, et al. oropharyngeal viral kinetics in d83c‐48a0‐ae74‐ disease 2019 viral kinetics patients hospitalized with b3cce9a5eac3.pdf moderately severe COVID‐19. Evaluate the antiviral activity Open Forum Antiviral Activity and Safety of https://pubmed.ncbi.nl and safety of 11 June 2020 Infectious Darunavir/Cobicistat for the Treatment of RCT China Jun Chen, et al. NCT04252274 Darunavir, Cobicistat m.nih.gov/32671131/ darunavir/cobicistat (DRV/c) Diseases COVID‐19 for treating mild COVID‐19 lopinavir/ritonavir; SN Systematic arbidol; https://link.springer.co To assess the current evidence Comprehensive Systematic and Statistical Review of review & Juan A. Siordia Jr et hydroxychloroquine; 15‐Jul‐20 USA m/article/10.1007%2Fs4 N/A regarding human controlled Clinical Coronavirus Disease 19 Treatment Trials Meta‐ al. remdesivir; 2399‐020‐00399‐6 COVID‐19 treatment trials. Medicine analysis tocilizumab; favipiravir; heparin; https://www.researchga Compared outcomes of A Randomized Trial of Ivermectin‐ Abu Taiub te.net/profile/Abu_Taiu Ivermectin, Ivermectin‐Doxycycline vs. BMC Infectious Doxycycline and Hydroxychloroquine‐ Banglades Mohammed b_Mohammed_Mohiud Doxycycline, Hydroxychloroquine‐ Preprint RT NCT04434144 Diseases Azithromycin therapy on COVID19 h Mohiuddin din_Chowdhury2/public Hydroxychloroquine, Azithromycin combination patients. Chowdhury, et al. ation/342159343_A_co Azithromycin therapy COVID19 patients mparative observationa with mild to moderate Assess the effectiveness of Internation https://www.cochraneli Convalescent plasma or hyperimmune Convalescent plasma, convalescent plasma and Systematic al brary.com/cdsr/doi/10.1 updated 12/10/20 Cochrane immunoglobulin for people with Piechotta V, et al. NA hyperimmune hyperimmune review Collaborati 002/14651858.CD01360 COVID‐19: a living systematic review immunoglobulin immunoglobulin for treating on 0.pub2/abstract people with COVID19

A Randomized, Open‐label, Controlled https://onlinelibrary.wil Advanced Clinical Trial of Azvudine Tablets in the ChiCTR2000029 Efficacy of azvudine in treating Preprint RCT China Zhigang Ren, et al. ey.com/doi/epdf/10.100 Azvudine Science Treatment of Mild and Common COVID‐ 853 mild COVID19 patients 2/advs.202001435 19, A Pilot Study Effect of Colchicine vs Standard Care on To evaluate the effect of JAMA Network Cardiac and Inflammatory Biomarkers https://jamanetwork.co treatment with colchicine on Randomize Open: and Clinical Outcomes in Patients m/journals/jamanetwor cardiac and inflammatory 24/06/2020 d clinical Greece Deftereos et al. NCT04326790 Colchicine Infectious Hospitalized With Coronavirus Disease kopen/fullarticle/27675 biomarkers and clinical trial Diseases 2019The GRECCO‐19 Randomized Clinical 93 outcomes in patients Trial hospitalized with COVID‐19. The Is febuxostat effective in International Febuxostat Therapy in Outpatients With https://pubmed.ncbi.nl IRCT201907270 Hydroxychloroquine, 30‐Jun‐20 RCT Iran Davoodi et al. comparision with Journal of Suspected COVID‐19: A Clinical Trial m.nih.gov/32603531/ 4434N1 febuxostat hydroxychloroquine? Clinical Practice https://www.nejm.org/d oi/pdf/10.1056/NEJMoa Effect of Dexamethasone in Hospitalized Horby et al. ISRCTN To test the effectiveness of 2021436?casa_token=H 17 July 2020 NEMJ Patients with COVID‐19: Preliminary RCT UK (RECOVERY Writing 50189673, Dexamethasone dexamethasone in patients 8GAcaEgprUAAAAA:m_9 Report Committee) NCT04381936 hospitalized with COVID‐19 Qlb5FCP6d6YPLPMryKLq VP0QTUouiQsD39ki 1j8 To determine whether a 6‐day https://www.medrxiv.or course of intravenous GLUCOCOVID: A controlled trial of EudraCT g/content/10.1101/2020 methylprednisolone (MP) 18‐Jun medRxiv methylprednisolone in adults hospitalized RCT Spain Corral‐Gudino et al. number: 2020‐ methylprednisolone .06.17.20133579v1.full.p improves outcome in patients with COVID‐19 pneumonia 001934‐37 df with SARS CoV‐2 infection at risk of developing Acute

https://immunology.scie Science Inhibition of Bruton tyrosine kinase in Is acalabrutinib effective in 05‐Jun‐20 RCT USA Roschewski et al. ncemag.org/content/5/ NA Acalabrutinib Immunology patients with severe COVID‐19 severe COVID‐19 patients? 48/eabd0110

Were the non‐pharmaceutical 8 June 2020 ‐ Estimating the effects of non‐ https://www.nature.co interventions implemented in Non‐pharmaceutical Accelerated Nature pharmaceutical interventions on COVID‐ Modelling UK Seth Flaxman, et al. m/articles/s41586‐020‐ NA European countries effective interventions publication 19 in Europe 2405‐7 in limiting the spread of SARS CoV‐2? The Janus kinase 1/2 inhibitor ruxolitinib https://www.nature.co Nature ‐ Retrospecti Efficacy and safety of 8 May 2020 in COVID‐19 with severe systemic Germany F. La Rosée, et al. m/articles/s41375‐020‐ Ruxolitinib Leukemia ve analysis ruxolitinib in severe COVID19 hyperinflammation 0891‐0

https://www.sciencedir Is canakinumab a safe and Lancet Canakinumab in a subgroup of patients Retrospecti Claudio Ucciferri, et ect.com/science/article/ 8 June 2020 Italy NA Canakinumab effective treatment against Reheumatology with COVID‐19 ve analysis al. pii/S2665991320301673 COVID19? ?via%3Dihub

Use of personal protective equipment To examine the protective against coronavirus disease 2019 by Observatio https://www.bmj.com/c effects of appropriate 10‐Jun‐20 BMJ China Min Liu et al. NA NA healthcare professionals in Wuhan, nal study ontent/369/bmj.m2195 personal protective China: cross sectional study equipment

https://www.thelancet.c Effects of non‐pharmaceutical What is the impact of om/journals/lanpub/arti The Lancet interventions on COVID‐19 cases, deaths, Modelling different control measures for 02‐Jun‐20 UK Gavines et al. cle/PIIS2468‐ NA NA Digital Healt and demand for hospital services in the study mitigating the burden of 2667(20)30133‐ UK: a modelling study COVID‐19 X/fulltext#%20

Clinical performance of the Luminex Journal of https://jcm.asm.org/con NxTAG CoV Extended Panel for SARS‐CoV‐ Jonathan Hon‐Kwan Evaluation of Luminex NxTAG 01‐Jun‐20 Clinical Diagnostic Hong‐Kong tent/early/2020/05/29/J NA Nucleic acid test 2 detection in nasopharyngeal specimens Chen in COVID‐19 detection Microbiology CM.00936‐20 of COVID‐19 patients in Hong Kong

Systematic https://www.sciencedir Clinical Clinical evidence for repurposing review / Australia/S ect.com/science/article/ Hydroxychloroquine, Does hydroxychloroquine 26‐May‐20 Microbiology chloroquine and hydroxychloroquine as Rodrigo et al. NA Meta‐ ri Lanka pii/S1198743X20302937 chloroquine have antiviral effect? and Infection antiviral agents: a systematic review analysis ?via%3Dihub To test the performance Kinetics of the humoral immune response https://www.medrxiv.or characteristics of seven to SARS‐CoV‐2: comparative analytical g/content/10.1101/2020 commercially available 14‐Jun MedRxiv Diagnostic Belgium Herroelen et al. N/A Antibody test performance of seven commercial .06.09.20124719v2.full.p serology tests for detection of serology tests df antibodies against the SARS‐ CoV‐2 https://www.medrxiv.or Therapeutic effectiveness of interferon‐ To assess the therapeutic observatio g/content/10.1101/2020 09‐Jun MedRxiv alpha 2b against COVID‐19: the Cuban Cuba Pereda et al. RPCEC00000318 Interferon alpha 2b efficacy of IFN‐α2b in patients nal study .05.29.20109199v1.full.p experience infected with SARS‐CoV‐2 df

To determine whether ICON (Ivermectin in COvid Nineteen) https://www.medrxiv.or Ivermectin is associated with study: Use of Ivermectin is Associated Retrospecti Cepelowicz Rajter g/content/10.1101/2020 10‐Jun MedRxiv USA N/A Ivermectin lower mortality rate in with Lower Mortality in Hospitalized ve analysis et al. .06.06.20124461v2.full.p patients hospitalized with Patients with COVID19 df COVID‐19 To assess the efficacy of prospectiv https://www.medrxiv.or lenzilumab therapy in patients First Clinical Use of Lenzilumab to e study g/content/10.1101/2020 hospitalized with severe 14‐Jun MedRxiv Neutralize GM‐CSF in Patients with with FDA USA Temesgen et al. N/A Lenzilumab .06.08.20125369v2.full.p COVID‐19 pneumonia, who Severe and Critical COVID‐19 Pneumonia emergency df had clinical and/or biomarker use IND evidence for increased risk of To investigate whether Low levels of the prognostic biomarker https://www.medrxiv.or soluble urokinase prospectiv suPAR are predictive of mild outcome in Denmark/ g/content/10.1101/2020 plasminogen activator 02‐Jun MedRxiv e cohort Eugen‐Olsen et al. N/A Prognostic biomarker patients with symptoms of COVID‐19 ‐ a USA .05.27.20114678v1.full.p receptor (suPAR) can aid in study prospective cohort study df identifying patients with low risk of respiratory failure when To determine if Low Dose‐ Low‐Dose Whole‐Lung Radiation for https://www.medrxiv.or Radiation Therapy can reduce COVID‐19 Pneumonia: Planned Day‐7 g/content/10.1101/2020 08/06/2020 MedRxiv CT USA Hess et al. NCT: 04366791 Low dose radiation pulmonary inflammation Interim Analysis of a Registered Clinical .06.03.20116988v1.full.p associated with COVID‐19 Trial df pneumonia.

https://www.medrxiv.or To evaluate the safety and Efficacy and Safety of Leflunomide for g/content/10.1101/2020 ChiCTR2000030 efficacy of leflunomide for the 02‐Jun MedRxiv Refractory COVID‐19: An Open‐label CT China Wang et al. Leflunomide .05.29.20114223v1.full.p 058 treatment of refractory COVID‐ Controlled Study df 19 in adult patients.

To explore the effect of high https://www.medrxiv.or Nano short peptide nutrition intervention fiber whey short peptide Retrospecti g/content/10.1101/2020 08‐Jun MedRxiv on the prognosis of patients with COVID‐ China Zhang et al. N/A enteral nutrition enteral nutrition on the ve analysis .06.03.20083980v1.full.p 19 prognosis of patients with df COVID‐19 To determine if ozonated https://www.medrxiv.or autohemotherapy is Ozone therapy for patients with SARS‐ prospectiv Spain/ g/content/10.1101/2020 associated with a shorter time 05‐Jun MedRxiv COV‐2 pneumonia: a single‐center e cohort USA/Canad Hernández et al. N/A Ozone therapy .06.03.20117994v1.full.p to clinical improvement in prospective cohort study study a df patients with severe COVID‐19 pneumonia. To determine the effect of https://www.medrxiv.or Center for Genetic CIGB‐258 immunomodulatory peptide: a Venegas‐Rodriguez g/content/10.1101/2020 CIGB‐258 immuno‐ Engineering and 02‐Jun MedRxiv novel promising treatment for critical and CT Cuba RPCEC00000313 et al. .05.27.20110601v1.full.p modulatory peptide Biotechnology (CIGB)‐258 severe COVID‐19 patients df therapy in seriously, or critically ill patients with To determine the clinical A cohort study to evaluate the effect of https://www.medrxiv.or outcomes of older COVID‐19 combination Vitamin D, Magnesium and Vitamin D, Observatio Chuen Wen Tan et g/content/10.1101/2020 patients who received Vitamin 02‐Jun MedRxiv Vitamin B12 (DMB) on progression to Singapore N/A Magnesium and nal study al. .06.01.20112334v1.full.p D, Magnesium and Vitamin severe outcome in older COVID‐19 Vitamin B12 (DMB) df B12 (DMB) compared to those patients. who did not To evaluate differences in https://www.medrxiv.or morbidity and mortality Therapeutic Anticoagulation Is Associated Retrospecti g/content/10.1101/2020 anticoagulation among mechanically 03‐Jun MedRxiv with Decreased Mortality in Mechanically USA Trinh et al. N/A ve analysis .05.30.20117929v1.full.p agents ventilated patients with Ventilated COVID‐19 Patients df COVID‐19 treated with therapeutic versus https://translational‐ EudraCT (2020‐ To evaluate efficacy of Tocilizumab for patients with COVID‐19 medicine.biomedcentral 001110‐38); 21 October 2020 of Translational M CT Italy Perrone et al. Tocilizumab tocilizumab in COVID‐19 pneumonia. The TOCIVID‐19 phase 2 trial .com/articles/10.1186/s clinicaltrials.gov pneumonia patients. 12967‐020‐02573‐9 (NCT04317092) To compare SAMBA II SARS‐ prospectiv https://www.medrxiv.or CoV‐2 performance against Rapid point of care nucleic acid testing e clinical UK/South g/content/10.1101/2020 Nucleic acid the standard lab RTPCR test in 02/06/2020 MedRxiv for SARS‐CoV‐2 in hospitalised patients: a trial and Dami Collier, et al. NCT04326387 Africa .05.31.20114520v1.full.p diagnostic suspected COVID‐19 cases clinical trial and implementation study observatio df presenting to hospital, nal study followed by a hospital‐based To compare three fully https://www.medrxiv.or automated large‐scale Side by side comparison of three fully Diagnostic g/content/10.1101/2020 laboratory analyzer test 06‐Jun MedRxiv automated SARS‐CoV‐2 antibody assays compariso Austria Perkmann et al. N/A Antibody diagnostic .06.04.20117911v2.full.p systems, with particular with a focus on specificity n df emphasis on specificity, which is crucial for an adequate To describe initial experience Implementation and evaluation of a novel https://www.medrxiv.or using a commercially‐available Diagnostic real‐time multiplex assay for SARS‐CoV‐2: g/content/10.1101/2020 Nucleic acid multiplex two‐step nested 05‐Jun MedRxiv validation Australia Williams et al. N/A In‐field learnings from a clinical .06.03.20117267v1.full.p diagnostic tandem RT‐PCR assay for the study microbiology laboratory df detection of coronaviruses that infect humans, including To construct and validate a https://www.medrxiv.or Diagnostic for cell‐free assay to measure Diagnostic Detection of SARS‐CoV‐2 neutralizing USA/Switz g/content/10.1101/2020 indentifying suitable neutralizing antibodies in 02‐Jun MedRxiv validation Danh et al. N/A antibodies with a cell‐free PCR assay erland .05.28.20105692v1.full.p Convalescent plasma order to identify suitable study df donors donors of convalescent plasma https://www.medrxiv.or To evaluate the real‐world Diagnostic accuracy of a host response diagnostic g/content/10.1101/2020 ISRCTN1496667 diagnostic accuracy of FebriDx 02‐Jun MedRxiv point‐of‐care test for identifying COVID‐ clinical UK Clark et al. Diagnostic .05.27.20114512v1.full.p 3 for the identification of COVID‐ 19 evaluation df 19 in hospitalised adults

Alltest rapid lateral flow immunoassays is https://www.sciencedir To analyze the diagnostic Journal of reliable in diagnosing SARS‐CoV‐2 Diagnostic ect.com/science/article/ performance of one serologic August 2020 Spain García et al. NA NA Clinical Virology infection from 14 days after symptom assay pii/S1386653220302158 rapid test in COVID‐19 onset: A prospective single‐center study ?via%3Dihub patients

Poor‐sleep is associated with slow Effects of sleep quality on Brain, recovery from lymphopenia and an https://www.sciencedir recovery from lymphopenia Retrospecti 06‐Jun‐20 Behaviour and increased need for ICU care in China Zhang et al. ect.com/science/article/ NA NA and clinical outcomes in ve study Imunity hospitalized patients with COVID‐19: A pii/S0889159120309946 hospitalized patients with retrospective cohort study COVID‐19 To assess the overall benefit–risk of the use of Remdesivir in Treatment of COVID-19: A Systematic Miranda Davies, et https://doi.org/10.1007/ remdesivir as a treatment for 28 May 2020 Drug Safety UK NA Remdesivir Systematic Benefit–Risk Assessment review al. s40264‐020‐00952‐1 COVID‐19 compared with standard of care, placebo or other treatments To determine the frequency of Routine Venous Thromboembolism DOI: Venous venous thromboembolism Society of Prophylaxis May Be Inadequate in the Observatio Thomas K. 27 May 2020 USA 10.1097/CCM.00000000 NA thromboembolism (VT) in critically ill COVID19 Critical Care Hypercoagulable State of Severe nal study Maatman, et al. 00004466 prophylaxis patients who recieved Coronavirus Disease 2019 prophylaxis for VT.

Effect of Convalescent Plasma Therapy on Is convalescent plasma a safe Time to Clinical Improvement in Patients doi:10.1001/jama.2020. ChiCTR2000029 3 June 2020 JAMA RCT China Ling Li, et al. Convalescent Plasma and efficient treatment for With Severe and Life‐threatening COVID‐ 10044 757 severe COVID19? 19 ‐ A Randomized Clinical Trial

Journal of the https://www.sciencedir American Ramipril in High Risk Patients with COVID‐ Retrospecti Ignacio J. Amat‐ ect.com/science/article/ NCT03201185 To analyze if ramipril modifies Preprint Spain Ramipril College of 19 ve analysis Santos, et al. pii/S073510972035395X (source RCT) the risk for COVID‐19. Cardiology ?via%3Dihub Should health care workeers The need of health policy perspective to Systematic https://journals.plos.org wear surgical masks or N95 protect Healthcare Workers during COVID‐ review / Primiano Iannone, /plosone/article?id=10.1 respirators during the routine 3 June 2020 PlosOne Italy NA N95 respirators 19 pandemic. A GRADE rapid review on Meta‐ et al. 371/journal.pone.02340 care (not the N95 respirators effectiveness analysis 25 involving aerosol generating procedures) of COVID‐19 Investigate the effects of Physical distancing, face masks, and eye Internation physical distance, face masks, protection to prevent person‐to‐person PROSPERO: Systematic al https://doi.org/10.1016/ and eye protection on virus 1 June 2020 Lancet transmission of SARS‐CoV‐2 and COVID‐ Derek K Chu, et al. CRD420201770 PPE review collaborati S0140‐6736(20)31183‐1 transmission in health‐care 19: a systematic review and meta‐ 47 on and non‐health‐care (eg, analysis community) settings

Diabetes, Exposure to DPP‐4 inhibitors and COVID‐ Case Do DPP‐4 inhinbitors have a Gian Paolo Fadini, https://pubmed.ncbi.nl Preprint obesity & 19 among people with type 2 population Italy NA DPP‐4 inhibitors protective effect agains et al. m.nih.gov/32463179/ metabolism diabetes. A case‐control study study COVID19?

A Randomized Trial of https://www.nejm.org/d Is hydroxychloroquine USA / D.R. Boulware, et 03 June 2020 NEJM Hydroxychloroquine as Postexposure RCT oi/full/10.1056/NEJMoa NCT04308668. Hydroxychloroquine effective in post‐exposure Canada al. Prophylaxis for Covid‐19 2016638 prohylaxis therapy?

Can CRISPR technology Biosensors and Ultra‐sensitive and high‐throughput Diagnostic https://doi.org/10.1016/ Preprint USA Zhen Huang, et al. NA CRISPR RT‐PCR simplify RT‐PCR for SARS CoV2 Bioelectronics CRISPR‐Powered COVID‐19 diagnosis assay j.bios.2020.112316 and be effective for diagnos?

Famotidine Use is Associated with https://www.gastrojour Improved Clinical Outcomes in Do COVID19 patients taking Gastroenterolo Retrospecti Daniel E. Freedberg, nal.org/article/S0016‐ Preprint Hospitalized COVID‐19 Patients: A USA NA Famotidine famotidine have a lower risk gy ve study et al. 5085(20)34706‐ Propensity Score Matched Retrospective of intubation and/or death? 5/fulltext Cohort Study Internation Is a 5 day course of al https://www.nejm.org/d remedesivir as effective as a Remdesivir for 5 or 10 Days in Patients Jason D. Goldman, 27 May 2020 NEJM RCT collaborati oi/full/10.1056/NEJMoa NCT04292899 Remdesivir 10 course in treating with Severe Covid‐19 et al. on/ Gilead 2015301 moderately ill COVID19 Sciences patients?

Internation Is remdesivir an effective https://www.nejm.org/d Remdesivir for the Treatment of Covid‐19 al treatment for reducing time 22 May 2020 NEJM RCT J.H. Beigel, et al. oi/full/10.1056/NEJMoa NCT04280705 Remdesivir — Preliminary Report collaborati to recovery in COVID19 2007764 on patients? Journal of Ruxolitinib in treatment of severe To evaluate the efficacy and Allergy and coronavirus disease 2019 (COVID‐19): A https://doi.org/10.1016/ ChiCTR‐OPN‐ Preprint RCT China Yang Cao, et al. Ruxolitinib safety of ruxolitinib for Clinical multicenter, single‐blind, randomized j.jaci.2020.05.019 2000029580. patients with severe COVID19. Immunology controlled trial

Thymosin alpha 1 (Tα1) reduces the Clinical Is thymosin alpha a safe and mortality of severe COVID 19 by Retrospecti https://pubmed.ncbi.nl Preprint Infectious China Yueping Liu, et al. NA Thymosin alpha effective treatment for severe restoration of lymphocytopenia and ve study m.nih.gov/32442287/ Diseases COVID19? reversion of exhausted T cells

International HUMAN CORONAVIRUS DATA FROM https://www.sciencedir Level of protection confered Journal of C Raina MacIntyre, Preprint FOUR CLINICAL TRIALS OF MASKS AND Review Australia ect.com/science/article/ NA PPE by masks and respirators for Infectious et al. RESPIRATORS pii/S1201971220303994 common coronavirus. Diseases

https://www.thelancet.c Use of anakinra in patients om/journals/lanrhe/arti The Lancet Anakinra for severe forms of COVID‐19: a Cohort who were admitted to 29‐May‐20 France Huet et al. cle/PIIS2665‐ NA Anakinra Rheumatology cohort study study hospital for severe forms of 9913(20)30164‐ COVID‐19 8/fulltext Safety, tolerability, and immunogenicity https://www.thelancet.c of a recombinant adenovirus type‐5 om/journals/lancet/artic Are different doses of Ad5 Ad5 vectored COVID‐ 22‐May‐20 The Lancet vectored COVID‐19 vaccine: a dose‐ CT China Feng‐Cai Zhu et al. le/PIIS0140‐ NCT04313127 vectored COVID‐19 vaccine 19 vaccine escalation, open‐label, non‐randomised, 6736(20)31208‐ safe and immunogenic? first‐in‐human trial 3/fulltext A comparative study on the time to achieve negative nucleic acid testing and https://www.researchsq Antiviral effect of danopevir or Comparativ Zhicheng Zhang et Danopevir and 29‐May‐20 Preprint hospital stays between Danoprevir and China uare.com/article/rs‐ NA lopinavir/ritonavir in COVID‐ e study al. lopinavir/ritonavir Lopinavir/Ritonavir in the treatment of 28376/v1.pdf 19 patients patients with COVID‐19

Potential of Arbidol for Post‐exposure https://link.springer.co Current Medical Prophylaxis of COVID‐19 Transmission–A Observatio Is Arbidol effective in 01‐Jun‐20 China Zhang et al. m/content/pdf/10.1007 NA Arbidol Science Preliminary Report of a Retrospective nal study profylaxis of COVID? /s11596‐020‐2203‐3.pdf Cohort Study

Advanced Interferon beta‐1a as a Candidate for http://ajem.tums.ac.ir/i Journal of IRCT201509140 Is interferon beta1a effective 26‐May‐20 COVID‐19 Treatment; An Open‐label CT Iran Payandemehr et al. ndex.php/ajem/article/v Interferon beta1a Emergency 24017N1 in treatment of COVID‐19? Single‐Arm Clinical Trial iew/454/307 Medicine

Efficacy and safety of interferon beta‐1a https://aac.asm.org/con To evaluate efficacy and Davoudi‐Monfared IRCT201002280 13 July 2020 Antiviral Agents in treatment of severe COVID‐19: A RCT Iran tent/early/2020/07/08/ Interferon beta‐1a safety of IFN β‐1a in patients et al. 03449N28 randomized clinical trial AAC.01061‐20 with severe COVID‐19.

Clinical https://www.medrxiv.or To develop and clinically A serological assay to detect SARS‐CoV‐2 Evaluation g/content/10.1101/2020 IRB protocol Antibody diagnostic evaluate an at‐home finger‐ 30/05/2020 medRxiv antibodies in at‐home collected of USA Karp et al. .05.29.20116004v2.full.p #20180015 test prick dried blood spot test to fingerprick dried blood spots diagnostic df detect SARS‐CoV‐2 antibodies test Clinical To assess the analytical and https://www.medrxiv.or Performance evaluation of the point‐of‐ Evaluation clinical performance of the UK/USA/So g/content/10.1101/2020 Nucleic acid 27/05/2020 medRxiv care SAMBA II SARS‐CoV‐2 Test for of Assennato et al. N/A SAMBA II 83 SARS‐CoV‐2 Test uth Africa .05.24.20100990v2.articl diagnostic test detection of SARS‐CoV‐2 diagnostic using panels and clinical e‐info test samples. Clinical https://www.medrxiv.or To develop and clincally Evaluation EasyCOV : LAMP based rapid detection of g/content/10.1101/2020 saliva RT‐LAMP evaluate a new simple saliva 30/05/2020 medRxiv of France L’Helgouach et al. N/A SARS‐CoV‐2 in saliva .05.30.20117291v1.full.p diagnostic test SARS‐CoV‐2 detection test diagnostic df based on RT‐LAMP technology test Clinical To evaluate the performance https://www.medrxiv.or Evaluation of performance of two SARS‐ Evaluation of two COVID 19 IgM/IgG g/content/10.1101/2020 Antibody rapid 27/05/2020 medRxiv CoV‐2 Rapid whole‐blood finger‐stick IgM‐ of France Prazuck et al. N/A Rapid Diagnostic Tests .05.27.20112888v1.full.p diagnostic test IgG Combined Antibody Tests diagnostic compared to the gold df test standard, RT‐PCR. To show the potential efficacy Mortality reduction in 46 severe Covid‐19 https://www.medrxiv.or and safety of hyperimmune proof of patients treated with hyperimmune g/content/10.1101/2020 plasma infusions, obtained 29/05/2020 medRxiv concept Italy Perotti et al. NCT 04321421 convalescent plasma plasma. A proof of concept single arm .05.26.20113373v1.full.p from convalescent donors, in study multicenter interventional trial df COVID‐19 patients with respiratory failure To analyse the outcomes of https://www.medrxiv.or COVID‐19 patients with Use of High Flow Nasal Therapy to Treat Retrospecti g/content/10.1101/2020 High Flow Nasal moderate‐to‐severe 26/05/2020 medRxiv Moderate to Severe Hypoxemic USA Patel et al. ve analysis .05.22.20109355v1.full.p Therapy hypoxemic respiratory failure Respiratory Failure in COVID‐19 df receiving High Flow Nasal Therapy https://www.thelancet.c Hydroxychloroquine or chloroquine with om/journals/lancet/artic Are these treatment regimens or without a with or without a macrolide Observatio USA/Switz 22‐May‐20 The Lancet Mehra et al. le/PIIS0140‐ NA Hydroxychloroquine associated with in‐hospital for treatment of COVID‐19: a nal study erland 6736(20)31180‐ death? multinational registry analysis 6/fulltext

Is Interferon‐a2b efficient in https://www.frontiersin. Frontiers in Canada, accelerating viral clearance 15 May 2020 Interferon‐a2b Treatment for COVID‐19 CT Qiong Zhou, et al. org/articles/10.3389/fim NA Interferon‐a2b Immunology China and reducing inflammation mu.2020.01061/full markers?

https://www.medrxiv.or To examine the role of early Clinical Early Short Course Corticosteroids in Retrospecti g/content/10.1101/2020 corticosteroid therapy in 19 May 2020 Infectious USA Fadel et al. NCT04374071 corticosteroids Hospitalized Patients with COVID‐19 ve study .05.04.20074609v1.full.p patients with moderate to Diseases df severe COVID‐19.

https://www.medrxiv.or Is convalescent plasma an Convalescent plasma treatment of severe Preprint medRxiv CT USA Sean T. H. Liu, et al. g/content/10.1101/2020 NA Convalescent plasma effective treatment for severe COVID‐19: A matched control study .05.20.20102236v1 COVID19? https://www.thelancet.c Use of renin–angiotensin–aldosterone Case om/journals/lancet/artic renin–angiotensin–ald system inhibitors and risk of COVID‐19 Francisco J de Does use of RAAS predispose 14 May 2020 Lancet population Spain le/PIIS0140‐ EUPAS34437 osterone system requiring admission to hospital: a case‐ Abajo, et al. patients to severe COVID19? study 6736(20)31030‐ inhibitors, RAAS population study 8/fulltext To evaluate various methods Resuscitation of the patient with of chest compressions in suspected/confirmed COVID‐19 when Randomize https://journals.viamedi Cardiology patients with Preprint wearing personal protective equipment: d crossover Poland Marek Malysz, et al. ca.pl/cardiology_journal NA PPE Journal suspected/confirmed SARS‐ A randomized multicenter crossover trial /article/view/68336 CoV‐2 infection conducted by simulation trial medical students wearing full Stefano Bonovas, https://www.nejm.org/d Re‐analysis of cumulative Compassionate Use of Remdesivir in Letters to Internation Gerd Fätkenheuer, 15 May 2020 NEJM oi/full/10.1056/NEJMc2 NA Remdesivir incidence of improvement, Covid‐19 (Grein et al. ‐ NEMJ) the editor al Christian Hoffman, 015312 patient classification Jiayuan Wu

https://www.clinicalmicr To evaluate the performance Clinical A multiple center clinical evaluation of an Diagnostic obiologyandinfection.co of an ultra‐fast single‐tube Preprint Microbiology ultra‐fast single‐tube assay for SARS‐CoV‐ clinical China Ji Wang, et al. m/action/showPdf?pii=S NA Diagnostic test nucleic acid isothermal and Infection 2 RNA evaluation 1198‐ amplification detection assay 743X%2820%2930284‐6 for SARS‐CoV‐2 RNA Are combined Diagnostic A combined oropharyngeal/nares swab is https://www.sciencedir Oropharyngeal/nares oropharyngeal/nares swab is a Journal of assay Preprint a suitable alternative to nasopharyngeal Canada Jason J., et al. ect.com/science/article/ NA and nasopharyngeal suitable alternative for Clinical Virology compariso swabs for the detection of SARS‐CoV‐2 pii/S1386653220301840 swabs nasopharyngeal swabs for n COVID19 sample colleciton? Can an AI model rapidly identify SARS‐CoV‐2 infection https://www.nature.co Artificial intelligence–enabled rapid Diagnostic AI diagnostic based on initial chest CT scans 19 May 2020 Nature Chinq Xueyan Mei, et al. m/articles/s41591‐020‐ N/A diagnosis of patients with COVID‐19 assay algorithm and associated clinical 0931‐3 information of COVID‐19 (+) patients in the early stage? To investigate the effects of dipeptidyl peptidase‐4 https://www.medrxiv.or dipeptidyl peptidase‐4 (DPP‐ Effects of a DPP‐4 inhibitor and RAS (DPP‐4i), retrospecti South Sang Youl Rhee et g/content/10.1101/2020 4i) and renin–angiotensin 23‐May Medrxiv blockade on clinical outcomes of patients N/A renin–angiotensin ve analysis Korea al. .05.20.20108555v1.full.p system (RAS) blockade on the with diabetes and COVID‐19 system (RAS) df short‐term clinical outcomes blockade of COVID‐19 https://www.medrxiv.or To investigate the prevalence Do COVID‐19 patients admitted to the prospectiv g/content/10.1101/2020 anti‐Pneumocystis of Pneumocystis jirovecii in 22‐May Medrxiv ICU require anti‐Pneumocystis jirovecii e cohort France Alanio N/A .05.18.20105296v1.full.p jirovecii prophylaxis COVID‐19 patients admitted prophylaxis? study df to the ICU To develop and validate a Development and clinical application of a novel RT‐LAMP assay capable https://www.medrxiv.or rapid and sensitive loop‐mediated RT‐LAMP Diagnostic of detecting SARS‐CoV‐2 RNA 23/05/2020 Medrxiv Diagnostic China Hu et al. g/content/10.1101/2020 N/A isothermal amplification test for SARS‐ test for potential use in centralized .05.20.20108530v2 CoV‐2 infection facilities and point‐of‐care settings https://www.medrxiv.or Use of siltuximab in patients with COVID‐ Efficacy of siltuximab for retrospecti g/content/10.1101/2020 22 May 2020 Medrxiv 19 pneumonia requiring ventilatory Italy, UK Gritti et al. NCT04322188 siltuximab treatment of severe patients ve analysis .04.01.20048561v3.full.p support with COVID‐19 df

https://www.medrxiv.or To test if intravenous Almitrine as a non ventilatory strategy to Case g/content/10.1101/2020 almitrine can improve hypoxia 22‐May Medrxiv improve intrapulmonary shunt in COVID‐ control France Losser et al. N/A Almitrine .05.18.20105502v1.full.p in mechanically ventilated 19 patients series df COVID‐19 patients. To examine the benefit‐risk https://www.medrxiv.or profile of remdesivir in COVID‐ Systematic Remdesivir in treatment of COVID‐19: A g/content/10.1101/2020 19 patients compared to 12‐May MedRxiv benefit‐risk UK Davies et al. N/A Remdesivir systematic benefit‐risk assessment .05.07.20093898v1.full.p standard assessment df of care, placebo or other treatments. Application https://www.medrxiv.or To test the hypothesis that Assisting Scalable Diagnosis Automatically of deep g/content/10.1101/2020 application of deep learning to 15‐May MedRxiv via CT Images in the Combat against learning to China Liu et al. N/A Chest CT .05.11.20093732v1.full.p 3D chest CT images could help COVID‐19 retrospecti df identify COVID‐19 infections. ve analysis To explore the association of https://www.medrxiv.or ACEi/ARB and/or statins with The effects of ARBs, ACEIs and statins on retrospecti g/content/10.1101/2020 clinical manifestations in 15‐May MedRxiv clinical outcomes of COVID‐19 infection Belgium De Spiegeleer et al. N/A ARBs, ACEi, Statins ve analysis .05.11.20096347v1.full.p COVID‐19 infected older among nursing home residents df people residing in nursing homes. To analyse key safety metrics https://www.medrxiv.or expanded following transfusion of Early Safety Indicators of COVID‐19 g/content/10.1101/2020 14‐May MedRxiv access USA Joyner et al. NCT04338360 Convalescent plasma convalescent plasma in Convalescent Plasma in 5,000 Patients .05.12.20099879v1.full.p program patients with severe or life‐ df threatening COVID‐19 To report the clinical course, Nebulized in‐line endotracheal dornase https://www.medrxiv.or safety, and outcomes after retrospecti Nebulized in‐line alfa and albuterol administered to g/content/10.1101/2020 nebulized in‐line endotracheal 15‐May MedRxiv ve case USA Weber et al. NCT04387786 endotracheal Dornase mechanically ventilated COVID‐19 .05.13.20087734v1.full.p dornase alfa treatment for study Alfa patients: A case series df intubated and mechanically ventilated patients with https://www.medrxiv.or To determine if transfusion of Treatment of COVID‐19 Patients with g/content/10.1101/2020 convalescent plasma is a safe 13‐May MedRxiv Case series USA Salazar et al. N/A Convalescent plasma Convalescent Plasma in Houston, Texas .05.08.20095471v1.full.p treatment option for those df with severe COVID‐19 disease. http://viruseradication.c om/journal‐ A review of the safety of favipiravir – a Journal of Virus Systematic Victoria Pilkington, details/A_review_of_the 30 April 2020 potential treatment in the COVID‐19 UK NA Favipiravir Safety of favipiravir Eradication review et al. _safety_of_favipiravir_% pandemic? E2%80%93_a_potential_ treatment in the COVI To evaluate the safety and Allogeneic cardiosphere-derived cells impact of administration of https://link.springer.co Basic Research (CAP-1002) in critically ill Siddharth Singh, et allogeneic CDCs, formulated 12 May 2020 Case series USA m/article/10.1007/s003 NA CAP‐1002 in Cardiology COVID-19 patients: compassionate-use al. for intravenous (IV) 95‐020‐0795‐1 case series infusion as CAP‐1002, in critically ill COVID‐19 patients. Efficacy and safety of corticosteroids in Canadian COVID‐19 based on evidence for COVID‐ Systematic Internation https://www.cmaj.ca/co Assess efficacy and safety of Medical 19, other coronavirus infections, Review ; al ntent/cmaj/early/2020/ corticosteroids for COVID19, Preprint Zhikang Ye, et al. NA Corticosteroids Association influenza, community‐acquired Meta‐ Collaborati 05/14/cmaj.200645.full. SARS, MERS, CAP, ARDS and Journal pneumonia and acute respiratory distress analysis on pdf influenza syndrome: a systematic review and meta‐ Pilot prospective open, single‐arm Clinical and https://www.clinexprhe To assess the efficacy and multicentre study on off‐label use of 1 May 2020 Experimental CT Italy S. Sciascia, et al. umatol.org/abstract.asp NA Tocilizumab safety of tocilizumab in severe tocilizumab in patients with severe COVID‐ Rheumatology ?a=15723 COVID19 patients 19

Efficacy of different facial BMJ Global Facial protection for healthcare workers Scoping Laura R Garcia https://gh.bmj.com/con protection devices, especially 23 April 2020 USA NA Facial protection Health during pandemics: a scoping review Review Godoy, et al. tent/5/5/e002553 in light of N95 respirator shortages

Compassionate remdesivir treatment of severe Covid‐19 pneumonia in intensive Comparative efficacy of Pharmacologica Spinello Antinori, et https://pubmed.ncbi.nl Preprint care unit (ICU) and Non‐ICU patients: Case series Italy NA Remdesivir remdesivir in ICU and non‐ICU l Research al. m.nih.gov/32407959/ Clinical outcome and differences in post patients treatment hospitalisation status To evaluate which type of full‐ Personal protective equipment for Internation https://www.cochraneli body PPE and which method preventing highly infectious diseases due Cochrane Systematic al brary.com/cdsr/doi/10.1 of donning or do.ing PPE have 15 April 2020 to exposure to contaminated body fluids Verbeek JH, et al. NA PPE Library Review Collaborati 002/14651858.CD01162 the least risk of contamination in healthcare on 1.pub4/full or infection for HCW, and staff which training methods To assess whether https://www.cochraneli convalescent plasma or Convalescent plasma or hyperimmune Cochrane Systematic Netherland brary.com/cdsr/doi/10.1 hyperimmune 14 May 2020 immunoglobulin for people with COVID‐ Valk SJ, et al. NA Convalescent Plasma Library Review s 002/14651858.CD01360 immunoglobulin transfusion is 19: a rapid review 0/full eJective and safe in the treatment of people with Journal of https://www.jacionline. Preliminary assessment of the Allergy and Safety and efficacy of early high‐dose IV Emanuele Pontali, org/article/S0091‐ Preprint Case series Italy NA Anakinra safety and efficacy of anakirna Clinical anakinra in severe COVID‐19 lung disease et al. 6749(20)30634‐ in severe/moderate COVID19 Immunology 5/fulltext

Tocilizumab for Treatment of Severe What is the role of COVID‐19 Patients: Preliminary Results Observatio https://pubmed.ncbi.nl 09 May 2020 Microorganisms Italy Colaneri et al. NA tocilizumab tocilizumab therapy in severe From SMAtteo COvid19 REgistry nal study m.nih.gov/32397399/ COVID‐19 patients? (SMACORE)

Hydroxychloroquine in Patients With https://www.bmj.com/c Is hydroxychloroquine Mainly Mild to Moderate Coronavirus ChiCTR2000029 14 May 2020 BMJ RCT China Tang et al. ontent/369/bmj.m1849. Hydroxychloroquine effective and safe in COVID‐19 Disease 2019: Open Label, Randomised 868 long patients? Controlled Trial

Clinical efficacy of hydroxychloroquine in patients with covid‐19 pneumonia who Observatio https://www.bmj.com/c Is hydroxychloroquine 05 May 2020 BMJ require oxygen: observational France Mahévas et al. NA Hydroxychloroquine nal study ontent/369/bmj.m1844 effective? comparative study using routine care data To assess and compare the Clinical https://www.medrxiv.or performance of 6 rapid tests Detection of SARS‐CoV‐2 antibodies using Evaluation g/content/10.1101/2020 Antibody diagnostic and 3 ELISAs for the diagnosis 08 May 2020 MedRxiv commercial assays and seroconversion of France Tuaillon et al. NCT04347850 .05.04.20090027v3.full.p test of COVID‐19, and to explore patterns in hospitalized patients diagnostic df seroconversions in subjects test with confirmed COVID‐19 Clinical https://www.medrxiv.or To compare the dynamic ddPCR: a more sensitive and accurate evaluation g/content/10.1101/2020 range and the limit of 08 May 2020 MedRxiv tool for SARS‐CoV‐2 detection in low viral of China Suo et al. PCR diagnostic test .02.29.20029439v2.full.p detection (LoD) between load specimens diagnostic df ddPCR and RT‐PCR test To evaluate the efficacy and Clinical Outcomes and Plasma https://www.medrxiv.or safety of adding baloxavir Concentrations of Baloxavir Marboxil and g/content/10.1101/2020 ChiCTR2000029 baloxavir marboxil, 05 May 2020 MedRxiv RCT China Yan Lou et al. marboxil or favipiravir to the Favipiravir in COVID‐19 Patients: an .04.29.20085761v1.full.p 544 favipiravir current standard antiviral Exploratory Randomized, Controlled Trial df treatment To determine if excessive https://www.medrxiv.or PGE2 may be a key in the Celebrex adjuvant therapy on COVID‐19: g/content/10.1101/2020 ChiCTR2000031 11 May 2020 MedRxiv Clinical trial China Wenxin Hong et al. Celebrex (Celecoxib) pathology of COVID‐19 and An experimental study .05.05.20077610v1.full.p 630 whether COX‐2 is a critical df target for therapy. retrospecti To take into account the ve analysis https://www.medrxiv.or possible confounders when COVID‐19 Related Mortality: Is the BCG of g/content/10.1101/2020 analyzing the difference in 05 May 2020 MedRxiv Mexico Paredes et al. N/A BCG Vaccine Truly Effective? Internation .05.01.20087411v1.full.p mortality rates between al mortality df countries with and without rates history of a universal BCG To determine if zinc sulfate Hydroxychloroquine and azithromycin retrospecti https://www.medrxiv.or zinc sulfate (as add‐on added to hydroxychloroquine plus zinc vs hydroxychloroquine and ve g/content/10.1101/2020 therapy to 08 May 2020 MedRxiv USA Carlucci et al. N/A and azithromycin may azithromycin alone: outcomes in observatio .05.02.20080036v1.full.p hydroxychloroquine improve outcomes among hospitalized COVID‐19 patients nal study df and azithromycin) hospitalized patients.

Systematic https://www.medrxiv.or To evaluate the effectiveness Efficacy of face mask in preventing review and g/content/10.1101/2020 of the use of masks to prevent 05 May 2020 MedRxiv respiratory virus transmission: a China Liang et al. N/A facemask meta‐ .04.03.20051649v3.full.p laboratory‐confirmed systematic review and meta‐analysis analysis df respiratory virus transmission.

Impact of corticosteroid therapy on Evaluate the safety and https://www.nature.co outcomes of persons with SARS‐CoV‐2, Meta‐ efficacy of corticosteroids on 5 May 2020 Nature China Huan Li, et al. m/articles/s41375‐020‐ NA Corticosteroids SARS‐CoV, or MERS‐CoV infection: a analyisis SARS‐CoV‐2, SARS‐CoV, and 0848‐3.pdf systematic review and meta‐analysis MERS‐CoV infections

Journal of Giulia https://www.biorxiv.org Can an efficient in‐silico trial Biomedical and In Silico Trial to test COVID‐19 candidate Preprint Russo, et Italy Giulia Russo, et al. /content/10.1101/2020. NA Vaccine base be developed, and can it Health vaccines: a case study with UISS platform al. 05.06.080630v1.full.pdf evaluate vaccine candidates? Informatics Were non‐pharmaceutical Effect of non‐pharmaceutical Mathemati https://www.nature.co interventions effective in interventions to contain COVID‐19 in China, UK, Non‐pharmaceutical Preprint Nature cal Shengjie Lai, et al. m/articles/s41586‐020‐ NA reducing the number of cases China US interventions Modeling 2293‐x_reference.pdf and speed of the epidemic in mainland China?

Continuous hydroxychloroquine or https://www.ncbi.nlm.ni Protective role of colchicine or Autoimmunity colchicine therapy does not prevent Retrospecti Omer Gendelman, Colchicine, 29 April 2020 Israel h.gov/pmc/articles/PMC NA hydroxychloriquine for Reviews infection with SARS‐CoV‐2: Insights from ve analysis et al. hydroxychloroquine 7198406/ COVID19 infection a large healthcare database analysis

Tocilizumab for the treatment of severe https://www.sciencedir COVID‐19 pneumonia with Is tocilizumab effective for Autoimmunity Observatio ect.com/science/article/ Preprint hyperinflammatory syndrome and acute Italy Paola Toniati, et al. NA Tocilizumab improving respiratory Reviews nal study abs/pii/S1568997220301 respiratory failure: A single center study condition in severe COVID19? 300 of 100 patients in Brescia, Italy

https://www.pnas.org/c Effective treatment of severe COVID‐19 Retrospecti ontent/pnas/early/2020 Efficacy and safety of April 29 2020 PNAS China Xiaoling Xua, et al. Tocilizumab patients with tocilizumab ve analysis /04/27/2005615117.full. tocilizumab in sever COVID19 pdf

Triple combination of interferon beta‐1b, https://www.thelancet.c lopinavir–ritonavir, and ribavirin in the om/journals/lancet/artic interferon beta‐1b, The efficacy and safety of 08 May 2020 The Lancet treatment of patients admitted to RCT Hong Kong Hung et al. le/PIIS0140‐ NCT04276688 lopinavir–ritonavir, combination hospital with COVID‐19: an open‐label, 6736(20)31042‐ ribavirin randomised, phase 2 trial 4/fulltext Interleukin‐1 blockade with high‐dose https://www.thelancet.c anakinra in patients with COVID‐19, acute om/journals/lanrhe/arti The Lancet Observatio 07 May 2020 respiratory distress syndrome, and Italy Cavalli et al. cle/PIIS2665‐ NCT04318366 anakinra Efficacy of anakinra Rheumatology nal study hyperinflammation: a retrospective 9913(20)30127‐ cohort study 2/fulltext

https://www.sciencedir Outcomes associated with TCZ Journal of Supportive Treatment with Tocilizumab Systematic ect.com/science/article/ 19 April 2020 USA Alzghari et al. NA NA treatment in patients with Clinical Virology for COVID‐19: A Systematic Review Review pii/S1386653220301220 COVID‐19 ?via%3Dihub

https://www.clinicalmicr Umifenovir treatment is not associated obiologyandinfection.co Effectiveness and safety of with improved outcomes in patients with Retrospecti 25 April 2020 Microbiology and China N. Lian, et al. m/article/S1198‐ NA Umifenovir (Arbidol) umifenovir for moderate coronavirus disease 2019: A retrospective ve CT 743X(20)30234‐ COVID‐19 study 2/fulltext

Is Baricitinib an effective drug https://www.ncbi.nlm.ni Baricitinib therapy in COVID‐19: A pilot Fabrizio Cantini, et for clinical and respiratory 16 April 2020 ournal of Infection CT Italy h.gov/pmc/articles/PMC NA Baricitinib study on safety and clinical impact al. improvement in moderate 7177073/ COVID19 patients?

https://www.medrxiv.or Mandated Bacillus Calmette‐Guérin (BCG) growth Does BCG vaccination serve as g/content/10.1101/2020 04 May 2020 medRxiv vaccination predicts flattened curves for curve USA Berg et al. N/A BCG vaccination a protective factor against .04.05.20054163v5.full.p the spread of COVID‐19 analysis COVID‐19 df

regression https://www.medrxiv.or Does TB Vaccination Reduce COVID‐19 analysis To assess the effectiveness of g/content/10.1101/2020 22 April 2020 medRxiv Infection? No Evidence from a Regression based on USA/ Japan Fukui et al. N/A BCG vaccination BCG vaccination against .04.13.20064287v1.full.p Discontinuity Analysis observatio COVID‐19 df nal data

https://www.medrxiv.or To determine the antiviral A Novel Protein Drug, Novaferon, as the g/content/10.1101/2020 ChiCTR2000029 Novaferon, 29 April 2020 medRxiv RCT China Fang Zheng et al. effects of Novaferon for Potential Antiviral Drug for COVID‐19 .04.24.20077735v1.full.p 496 Lopinavir/Ritonavir COVID‐19 df To summarise the data on all Review and methodological analysis of https://www.medrxiv.or currently tested treatment all treatment and trials currently testing treatment and Systematic Greece, g/content/10.1101/2020 and prevention options for 01 May 2020 medRxiv Fragkou et al. N/A preparation options prevention options for the novel review France .04.27.20080226v1.full.p COVID‐19, and to for covid‐19 coronavirus disease (COVID‐19) globally. df methodologically analyse and evaluate the quality of the https://www.medrxiv.or Could hydroxychloroquine Hydroxychloroquine application is retrospecti g/content/10.1101/2020 administration be beneficial in 01 May 2020 medRxiv associated with a decreased mortality in China Bo Yu et al. N/A Hydroxychloroquine ve analysis .04.27.20073379v1.full.p the treatment of critically ill critically ill patients with COVID‐19 df patients with COVID‐19?

https://www.medrxiv.or To determine if anti‐ Hypertension and Renin‐Angiotensin‐ retrospecti g/content/10.1101/2020 anti‐hypertensive hypertensive drugs are 29 April 2020 medRxiv Aldosterone System Inhibitors in Patients USA Ip et al. N/A ve analysis .04.24.20077388v1.full.p agents harmful or beneficial to Covid‐ with Covid‐19 df 19 patients with hypertension To evaluate the antiviral Lopinavir‐ritonavir alone or combined https://www.medrxiv.or efficacy of lopinavir/ritonavir with arbidol in the treatment of 73 retrospecti g/content/10.1101/2020 lopinavir/ritonavir, alone or combined with 29 April 2020 medRxiv China Xiu Lan et al. N/A hospitalized patients with COVID‐19: a ve analysis .04.25.20079079v1.full.p arbidol arbidol in the treatment of pilot retrospective study df hospitalized patients with COVID‐19. Preliminary evidence from a multicenter prospectiv https://www.medrxiv.or To assess the efficacy and prospective observational study of the e Mingxing Huang et g/content/10.1101/2020 04 May 2020 medRxiv China ChiCTR200002960 Chloroquine safety of chloroquine with safety and efficacy of chloroquine for the observatio al. .04.26.20081059v1.full.p different doses in COVID‐19 treatment of COVID‐19 nal study df

To evaluate the effects of https://www.medrxiv.or QT Interval Prolongation and Torsade De Hydroxychloroquine/Azithrom retrospecti g/content/10.1101/2020 Hydroxychloroquine, 01 May 2020 medRxiv Pointes in Patients with COVID‐19 treated USA/Italy Chorin et al. N/A ycin on the QT interval and ve analysis .04.27.20074583v1.full.p Azithromycin with Hydroxychloroquine/Azithromycin the arrhythmic risk in patients df with SARS‐CoV‐2 infection.

https://www.medrxiv.or To assess and compare all diagnostic Performance & Quality Evaluation of David Surace g/content/10.1101/2020 nucleic acid‐based COVID‐19 01 May 2020 medRxiv kit China N/A qPCR Diagnostic test Marketed COVID‐19 RNA Detection Kits Kapitula et al. .04.25.20080002v1.full.p testing kits from quality evaluation df control perspectives azithromycin, To determine the relative risk https://www.medrxiv.or chloroquine, of drug‐induced Long QT Risk of drug‐induced Long QT Syndrome Systematic USA/Canad g/content/10.1101/2020 favipiravir, Syndrome (LQTS) associated 29 April 2020 medRxiv associated with the use of repurposed Michaud et al. N/A review a .04.21.20066761v2.full.p hydroxychloroquine, with SARS‐CoV‐2 (COVID‐19) COVID‐19 drugs: a systematic review df lopinavir/ritonavir, proposed repurposed drugs remdesivir compared to well‐known retrospecti To evaluate the risk of ve analysis, https://www.medrxiv.or overdose for chloroquine Concentration‐dependent mortality of Bayesian Thailand/ g/content/10.1101/2020 29 April 2020 medRxiv Watson et al. N/A Chloroquine treatment or prevention chloroquine in overdose logostic UK/ France .04.24.20078303v1.full.p regimens currently being regression, df trialled in COVID19 pharmacod https://www.thelancet.c Remdesivir in adults with severe COVID‐ om/journals/lancet/artic Effect of remdesivir in COVID‐ 29 April 2020 The Lancet 19: a randomised, double‐blind, placebo‐ RCT China Wang et al. le/PIIS0140‐ NCT04257656 remdesivir 19 patients controlled, multicentre trial 6736(20)31022‐ 9/fulltext

A Rapid Systematic Review of Clinical Academic https://onlinelibrary.wil Trials Utilizing Chloroquine and Systematic Analyze current literature to 02 May 2020 Emergency USA Chowdhury et al. ey.com/doi/abs/10.1111 NA NA Hydroxychloroquine as a Treatment for review find the role of CQ and HCQ Medicine /acem.14005 COVID‐19.

Clinical Efficacy of Intravenous https://www.medrxiv.or To determine the clinical retrospecti intravenous Immunoglobulin Therapy in Critical g/content/10.1101/2020 efficacy of intravenous 20 April 2020 medRxiv ve cohort China Ziyun Shao et al. N/A immunoglobulin Patients with COVID‐19: A Multicenter .04.11.20061739v2.full.p immunoglobulin (IVIG) study (IVIG) therapy Retrospective Cohort Study df therapy in COVID‐19 patients.

pharmacok To establish best‐evidence to Chloroquine dosing recommendations for https://ascpt.onlinelibra Clin Pharmacol inetic Netherland inform pediatric Chloroquine 22 April 2020 pediatric COVID‐19 supported by Verscheijden et al. ry.wiley.com/doi/10.100 N/A Chloroquine Ther. (PBPK) s doses for children infected modeling and simulation. 2/cpt.1864 model with COVID‐19 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive https://jamanetwork.co To evaluate the safety & JAMA Network Therapy for Patients Hospitalized With m/journals/jamanetwor efficacy of different dosages 24 April 2020 RCT Brazil Borba et al NCT04323527 Chloroquine Open Severe Acute Respiratory Syndrome kopen/fullarticle/27654 of chloroquine in patients with Coronavirus 2 (SARS‐CoV‐2) Infection: A 99 severe COVID‐19. Randomized Clinical Trial. A Randomized, Single‐blind, Group https://www.medrxiv.or To evaluate the clinical sequential, Active‐controlled Study to g/content/10.1101/2020 ChiCTR2000029 efficacy and safety of α‐Lipoic 21 April 2020 medRxiv evaluate the clinical efficacy and safety of RCT China Zhong et al. α‐Lipoic acid (ALA) .04.15.20066266v1.full.p 851 acid (ALA) for critically ill α‐Lipoic acid for critically ill patients with df patients with COVID‐19. coronavirus disease 2019（COVID‐19） To systematically retrieve and Rapid summarize the current Effectiveness and Safety of https://www.medrxiv.or review and evidence of the effectiveness 22 April 2020 medRxiv Glucocorticoids to Treat COVID‐19: A China Shuya Lu et al g/content/10.1101/2020 N/A Glucocorticoids meta‐ and safety of glucocorticoid Rapid Review and Meta‐Analysis .04.17.20064469v1 analysis therapy for patients with COVID‐19 https://www.medrxiv.or To assess the effectiveness of A systematic review of Anakinra, Anakinra, Systematic g/content/10.1101/2020 specific interleukin‐1 and ‐6 26 April 2020 MedRxiv Tocilizumab, Sarilumab and Siltuximab for UK Khan et al N/A Tocilizumab, review .04.23.20076612v1.full.p inhibitors for the treatment of coronavirus‐related infections Sarilumab, Siltuximab df coronavirus‐related infections. https://www.cytodyn.co Preliminary m/newsroom/press‐ Southern California Patients Treated with results releases/detail/415/sout 13 April 2020 Press release Leronlimab for COVID‐19 under from USA CytoDyn INC. NA leronlimab Could leronlimab be effective? hern‐california‐patients‐ Emergency IND clinical trial treated‐with‐leronlimab‐ for

Transplantation of ACE2‐ Mesenchymal Efficacy of MSC Aging and http://dx.doi.org/10.143 ChiCTR2000029 ACE2‐mesenchymal 28 February 2020 Stem Cells Improves the Outcome of CT China Leng et al. transplantation in COVID Disease 36/AD.2020.0228 990 stem cell Patients with COVID‐19 Pneumonia patients

Journal of https://onlinelibrary.wil What are treatment responses Tocilizumab treatment in COVID‐19: a Observatio 26 March 2020 Medical China Luo et al. ey.com/doi/full/10.1002 NA tocilizumab of TCZ in the COVID‐19 single center experience nal study Virology /jmv.25801 patients?

Association of Inpatient Use of Angiotensin‐ To determine the association Angiotensin Converting Enzyme Inhibitors https://www.ahajournal converting enzyme between in‐hospital use of Circulation Observatio 17 April 2020 and Angiotensin II Receptor Blockers with China Zhang et al. s.org/doi/10.1161/CIRCR NA inhibitors (ACEIs) and ACEI/ARB and all‐cause Research nal study Mortality Among Patients With ESAHA.120.317134 Angiotensin receptor mortality in COVID‐19 patients Hypertension Hospitalized With COVID‐19 blockers (ARBs) with hypertension Asses the association between Association of Renin‐Angiotensin System Angiotensin‐ ACEIs/ARBs and severity of Inhibitors With Severity or Risk of Death https://jamanetwork.co converting enzyme illness and mortality in 23 April 2020 JAMA in Patients With Hypertension Case series China Juy Li, et al m/journals/jamacardiolo NA inhibitors (ACEIs) and patients with hypertension Hospitalized for Coronavirus Disease 2019 gy/fullarticle/2765049 Angiotensin receptor hospitalized for COVID‐19 (COVID‐19) Infection inWuhan, China blockers (ARBs) infection.

Acta Potential therapeutic effects of https://www.sciencedir Is treatment with dipyridamol PrePrint Pharmaceutica dipyridamole in the severely ill patients RCT China Xiaoyan Liu, et al. ect.com/science/article/ NA Dipyridamole clinically effetive in severly ill Sinica B with COVID‐19 pii/S2211383520305529 COVID19 patients?

Benefits and Risks of Chloroquine and https://www.medrxiv.or meta‐ To evaluate the efficacy and Hydroxychloroquine in The Treatment of g/content/10.1101/2020 chloroquine/hydroxyc 18 April 2020 medRxiv analysis of China/ USA Jing Wang et al safety of Chloroquine and Viral Diseases: A Meta‐Analysis of .04.13.20064295v1.full.p horoquine RCTs hydroxychloroquine Placebo Randomized Controlled Trials df To assess the effectiveness of Physical interventions to interrupt or systematic Saudi https://www.medrxiv.or hand hygiene, surface reduce the spread of respiratory viruses. review and Arabia, g/content/10.1101/2020 disinfecting, and other 20 April 2020 medRxiv Part 2 ‐ Hand hygiene and other hygiene Al‐Ansary NA hygiene interventions meta‐ Australia, .04.14.20065250v1.full.p hygiene interventions in measures: systematic review and meta‐ analysis Canada df preventing or reducing the analysis. spread of illnesses from To investigate the efficacy and An experimental trial of recombinant https://www.medrxiv.or Recombinant human safety of recombinant human human interferon alpha nasal drops to g/content/10.1101/2020 17 April 2020 medRxiv Clinical trial China Meng et al. NCT04320238 interferon‐alpha nasal interferon alpha1b (rhIFN‐α) prevent coronavirus disease 2019 in .04.11.20061473v1.full.p drops nasal drops in healthy medical medical staff in an epidemic area df staff to prevent COVID‐19. An exploratory randomized, controlled study on the efficacy and safety of https://www.medrxiv.or Lopinavir‐Ritonavir 23 March 2020, lopinavir/ritonavir or arbidol treating g/content/10.1101/2020 lopinavir/ritonavir combination compared to updated 15 April medRxiv RCT China Li et al. NCT04252885 adult patients hospitalized with .03.19.20038984v2.full.p (Kaletra), arbidol Arbidol compared to no 2020 mild/moderate COVID‐19 (ELACOI) df antiviral treatment

Potential Effectiveness and Safety of https://www.medrxiv.or To assess the potential review and Antiviral Agents in Children with g/content/10.1101/2020 effectiveness and safety of 17 April 2020 medRxiv meta‐ China Shi et al. NA antivirals Coronavirus Disease 2019: A Rapid .04.13.20064436v1.full.p antiviral agents for COVID‐19 analysis Review and Meta‐Analysis df in children.

https://www.medrxiv.or The aim of this review was to Efficacy and Safety of Antibiotic Agents in g/content/10.1101/2020 evaluate the efficacy and 17 April 2020 medRxiv rapid review China Wang et al NA antibiotics Children with COVID‐19: A Rapid Review .04.13.20064402v1.full.p safety of antibiotic agents in df children with COVID‐19

No evidence of rapid antiviral clearance Prospectiv https://www.sciencedir Is hydroxychloroquine Médécine et or clinical ben‐efit with the combination e ect.com/science/article/ Hydroxychloroquine, effecitve for viral clearance Preprint Maladies of hydroxychloroquine and azithromycin France JM Molina et al. NA virological pii/S0399077X20300858 azithromycin when reproducing the study Infectieuses in patients with severe COVID‐19 assay ?via%3Dihub of Gautrel et al.? infection Grant from the https://www.sciencedir National The effect of corticosteroid treatment on Evaluate the influence of Accepted 31 Journal of Meta‐ ect.com/science/article/ Natural Science patients with coronavirus infection: a China Zhenwei Yang, et al. Corticosteroids corticosteroids in patients March 2020 Infection analysis pii/S0163445320301912 Foundation of systematic review and meta‐analysis with coronavirus. ?via%3Dihub China (Jing Liu, grant no.

Clinical Towards Optimization of https://academic.oup.co What is the best dose of Prospectiv Preprint Infectious Hydroxychloroquine Dosing in Intensive France Sophie Perinel et al, m/cid/article/doi/10.109 NA Hydroxychloroquine hydroxychloroquine for e PK study Diseases Care Unit COVID‐19 Patients 3/cid/ciaa394/5816960 COVID19 patients?

https://academic.oup.co Is cholorquine better than Journal of Mingxing Huang, et m/jmcb/article/doi/10.1 Chloroquine, lopinavir/ritonavir in severe Molecular Cell Treating COVID‐19 with Chloroquine RCT China NA al. 093/jmcb/mjaa014/581 lopinavir, ritonavir and moderate COVID19 Biology 4655 patients?

UK, https://www.nejm.org/d Compassionate Use of Remdesivir for Canada, 10 April 2020 NEJM Report Grein et al. oi/full/10.1056/NEJMoa NA Remdesivir NA Patients with Severe Covid‐19 Europe, 2007016 Japan

https://www.sciencedir A systematic review on the efficacy and Summary of the existing the Journal of Systematic Andrea Cortegiani, ect.com/science/article/ 10 March 2020 safety of chloroquine for the treatment of Italy NA Chloroquine evidence on chloroquine for Critical Care review et al. pii/S0883944120303907 COVID‐19 the treatment of COVID‐19 ?via%3Dihub Systematic review of the Systematic review of the efficacy and clinical outcomes of using Journal https://onlinelibrary.wil safety of antiretroviral drugs against Systematic antiretroviral drugs for the Preprint International Switzerland N Ford et al. ey.com/doi/10.1002/jia2 NA Antiretroviral drugs SARS, MERS, or COVID‐19: initial review prevention and treatment of AIDS Society .25489 assessment coronaviruses and planned clinical trials Ethics Investigate the effects of 6‐ committees of week respiratory Complementary Respiratory rehabilitation in elderly Non‐ https://www.sciencedir Hainan General Respiratory rehabilitation training on 30 March 2020 Therapies in patients with COVID‐19: A randomized interventio China Kai Liu, et al. ect.com/science/article/ Hospital and rehabilitation training respiratory function, QoL, Clinical Practice controlled study nal RCT pii/S1744388120304278 Huanggang mobility and psychological Central Hospital function in elderly patients Investigate the effect of Complementary Effects of progressive muscle relaxation Non‐ https://www.sciencedir Progressive muscle progressive muscle relaxation 6 March 2020 Therapies in on anxiety and sleep quality in patients interventio China Kai Liu, et al. ect.com/science/article/ NA relaxation (sleep on anxiety and sleep quality of Clinical Practice with COVID‐19 nal RCT pii/S1744388120302784 therapy) COVID‐19 patients

First Clinical Study Using HCV Protease https://www.medrxiv.or Inhibitor Danoprevir to Treat Naïve and g/content/10.1101/2020 Effect of danoprevir in 24 March 2020 MedRxiv CT China Chen et al. NCT04291729 danopevir/ritonavir Experienced .03.22.20034041v1.full.p moderate COVID‐19 patients COVID‐19 Patients df

The potential of low molecular weight https://www.medrxiv.or heparin to mitigate cytokine storm in Retrospecti 07 April 2020 MedRxiv China Chen Shi et al. g/content/10.1101/2020 not found enoxaparin Efficacy of enoxaparin severe covid‐19 patients: a retrospective ve CT .03.28.20046144v2 clinical study No evidence of clinical efficacy of hydroxychloroquine in patients https://www.medrxiv.or To assess the effectiveness of hospitalised for COVID‐19 infection and Retrospecti Matthieu Mahévas g/content/10.1101/2020 14 April 2020 MedRxiv France NA Hydroxychloroquine Hydroxychloroquine in requiring oxygen: results of a study using ve analysis et al. .04.10.20060699v1.full.p patients with severe Covid‐19 routinely collected data to emulate a df target trial Grants: National Science and https://jamanetwork.co Is plasma from convalescente Treatment of 5 critically ill patients with Observatio Technology 27 March 2020 JAMA China C Shen, et al. m/journals/jama/fullarti Convalescent plasma patients beneficial for COVID‐19 with convalescent plasma nal study Major Project cle/2763983 critically ill COVID19 patients? (2018ZX107110 01, Proceedings of the National Observatio Is treatment with The feasibility of convalescent plasma https://www.pnas.org/c Academy of nal/retrosp ChiCTR2000030 convalescent plasma safe and 6 April 2020 therapy in severe COVID‐19 patients: a China Kai Duan et al ontent/early/2020/04/0 Convalescent plasma Sciences of the ective 048 beneficial for COVID19 pilot study 2/2004168117 United States of control patients? America Compare medical masks to Influenza and Medical Masks vs N95 Respirators for N95 respirators in preventing https://onlinelibrary.wil other Preventing COVID‐19 in Health Care Systematic Jessica J Bartoszko, N95 respirators vs laboratory confirmed viral Preprint Canada ey.com/doi/pdf/10.1111 NA Respiratory Workers ‐ A Systematic Review and Meta‐ review et al. surgical masks infection and respiratory /irv.12745 Viruses Analysis of Randomized Trials illness including coronavirus specifically in health care https://www.cambridge. Is attending one live training RANDOMIZED TRIAL OF INSTRUCTOR‐LED Disaster org/core/journals/disast session or watching video TRAINING VERSUS VIDEO LESSON IN Medicine and er‐medicine‐and‐public‐ Training on personal trainings over a month more Preprint TRAINING HEALTH CARE PROVIDERS IN RCT Denmark L Christensen et al NA Public Health health‐ protective equipment effective for training on PROPER DONNING AND DOFFING OF Preparedness preparedness/article/ra downing and doffing personal PERSONAL PROTECTIVE EQUIPMENT ndomized‐trial‐of‐ protective equipment? Performance of VivaDiagTM COVID‐19 Journal of https://onlinelibrary.wil To assess an easy to perform IgM/IgG Rapid Test is inadequate for Diagnostic Irene Cassantini et Diagnostic serological Preprint Medical Italy ey.com/doi/epdf/10.100 NA serological assay for diagnosis diagnosis of COVID‐19 in acute patients assay al. assay Virology 2/jmv.25800 of COVID19 referring to emergency room department DOI: 10.1128/JC M.00461‐20; Evaluation of Nucleocapsid and Spike https://jcm.asm.org/con Joural of Clinical Diagnostic Hospital Ethics Diagnostic serological Evaluate the diagnostic Preprint Protein‐based ELISAs for detecting China Wanbing Liu, et al. tent/early/2020/03/27/J Microbiology assay Committee of assay feasibility of two ELISA assays antibodies against SARS‐CoV‐2 CM.00461‐20 the General Hospital of the Article originally Australian New published in 2015; A cluster randomised trial of cloth masks Zealand Clinical To compare the efficacy of Australia https://bmjopen.bmj.co medical masks, cloth authors added BMJ Open compared with medical masks in RCT MacIntyre CR et al. Trials Registry: cloth masks to medical masks /Vietnam m/content/5/4/e006577 masks comment on healthcare workers ACTRN1261000 in hospital healthcare workers 30/03/2020 0887077.

Efficacy of hydroxychloroquine in patients https://www.medrxiv.or ChiCTR2000029 Assess the efficacy of 31 March 2020 MedRxiv with COVID‐19: results of a randomized RCT China Zhaowei Chen et al. g/content/10.1101/2020 Hydroxychloroquine 559 hydroxychloroquine clinical trial .03.22.20040758v2

Clinical and microbiological effect of a https://www.mediterran combination of hydroxychloroquine and Assess the efficacy of ee‐infection.com/wp‐ Hydroxychloroquine, Preprint azithromycin in 80 COVID‐19 patients RCT France Gautret et al. NA hydroxychloroquine content/uploads/2020/0 Azithromycin with at least a six‐day follow up: an associated with azithromycin 3/COVID‐IHU‐2‐1.pdf observational study An exploratory randomized, controlled study on the efficacy and safety of Lopinavir‐Ritonavir 23 March 2020 https://www.medrxiv.or lopinavir/ritonavir or arbidol treating lopinavir/ritonavir combination compared to (preprint, not yet BMJ RCT China Li et al. g/content/10.1101/2020 NCT04252885 adult patients hospitalized with (Kaletra), arbidol Arbidol compared to no peer‐reviewed) .03.19.20038984v1 mild/moderate COVID‐19 (ELACOI) antiviral treatment ChiCTR2000029 Breakthrough: Chloroquine phosphate 939, https://www.jstage.jst.g has shown apparent efficacy in treatment Summary ChiCTR2000029 Could chloroquine be 10 Feb 2020 Biosci Trends China Gao et al. o.jp/article/bst/14/1/14 Chloroquine of COVID‐19 associated pneumonia in of 15 CTs 935, effective? _2020.01047/_article clinical studies. ChiCTR2000029 899, https://www.cytodyn.co Preliminary Three Additional Patients with Severe m/newsroom/press‐ results not published COVID‐19 Treated with Leronlimab in releases/detail/401/thre 30 March 2020 from USA CytoDyn Inc. NA Leronlimab Could leronlimab be effective? yet New York Medical Center Bringing the e‐additional‐patients‐ clinical trial Total to 10 Patients with‐severe‐covid‐19‐ treated‐with

https://www.medrxiv.or Favipiravir versus Arbidol for COVID‐19: A ChiCTR2000030 Conventional therapy + 27 March 2020 medRxiv RCT China Chang Chen et al. g/content/10.1101/2020 Favipiravir, Arbidol Randomized Clinical Trial 254 favipiravir or arbidol? .03.17.20037432v2

International https://www.sciencedir Hydroxychloroquine and azithromycin as EudraCT Journal of ect.com/science/article/ Hydroxychloroquine, Role of hydroxychloroquine on 20 March 2020 a treatment of COVID‐19: results of an CT France Gautret et al. number 2020‐ Antimicrobial pii/S0924857920300996 Azithromycin respiratory viral loads open‐label non‐randomized clinical trial 000890‐25 Agents #!

https://www.ncbi.nlm.ni Lopinavir‐Ritonavir A Trial of Lopinavir‐Ritonavir in Adults ChiCTR2000029 lopinavir/ritonavir 19 March 2020 N Engl J Med RCT China Cao et al. h.gov/pubmed/3218746 combination compared to Hospitalized with Severe Covid‐19. 308 (Kaletra) 4 conventional therapy ?

https://www.sciencedir Arbidol combined with LPV/r versus LPV/r Retrospecti Arbidol and lopinavir‐ritonavir Journal of ect.com/science/article/ Lopinavir/ritonavir, 11 March 2020 alone against Corona Virus Disease 2019: ve cohort China Lisi Deng NA compared to lopinavir‐ Infection pii/S0163445320301134 Arbidol A retrospective cohort study study ritonavir only? ?via%3Dihub What is the efficacy and safety High‐flow nasal‐oxygenation‐ assisted https://bjanaesthesia.or of high‐flow nasal oxygenation British Journal fibreoptic tracheal intubation in critically g/article/S0007‐ ChiCTR2000029 High‐flow nasal during fibreoptic In press RCT China Cai‐Neng Wu et al. of Anaesthesia ill patients with COVID‐19 pneumonia: a 0912(20)30135‐ 658 oxygnation bronchoscopic intubation in prospective randomised controlled trial 5/fulltext critically ill patients with COVID‐19?

Chinese Journal Efficacy of lopinavir, ritonavir and Arbidol 2020 Pre‐print Retrospecti http://rs.yiigle.com/yufa Lopinavir/ritonavir, Efficacy of lopinavir/ritonavir of Infectious for the treatment of new coronavirus China Chen Jun et al. NA online ve analysis biao/1182592.htm Arbidol and arbidol Diseases, pneumonia

Journal of Zhejiang http://www.zjujournals. A pilot study of hydroxychloroquine in University com/med/CN/10.3785/j. Role of hydroxychloroquine on 2020 treatment of patients with common RCT China Chen Jun et al. NCT04261517 Hydroxychloroquine (Medical issn.1008‐ respiratory viral loads coronavirus disease‐19 (COVID‐19) Science) 2020 , 9292.2020.03.03 Vol. 49 Issue Assess the efficacy and safety Meplazumab treats COVID‐19 of meplazumab, a humanized https://doi.org/10.1101/ 2020 Pre‐print MedRxiv pneumonia: an open‐labelled, concurrent CT China Huijie Bian et al. NCT 04275245 Meplazumab anti‐CD147 antibody, as add‐ 2020.03.21.20040691 controlled add‐on clinical trial on therapy in patients with COVID‐19 pneumonia.

Total